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Abstract

EX VIVO EXPANSION OF TUMOR-SPECIFIC T CELLS WITH SEQUENTIAL
COMMON GAMMA CHAIN CYTOKINES RENDER THEM REFRACTORY TO
MDSC UPON ADOPTIVE IMMUNOTHERAPY.

By Debasmita Basu, M.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master
of Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Masoud H. Manjili
Assistant Professor, Department of Microbiology and Immunology

Myeloid derived suppressor cells (MDSCs) are heterogeneous population of
immature cells at various stages of differentiation, characterized by the presence of
CD11b and Gr1 in mice. They are major contributors of the tumor-induced immune
suppression against the tumors. So far, various strategies have been introduced to

xi

overcome the endogenous MDSCs. Most of these approaches rely on the elimination
of MDSCs and it is not clear whether tumor-reactive T cells may be differentiated
towards phenotypes that are refractory to MDSCc. Our laboratory has previously
shown that high affinity T cells derived from tumor-sensitized wild-type FVB mice
and expanded ex vivo with the alternating common gamma chain cytokine
formulation (initiation of culture with IL-7 + IL-15 followed by one day pulse with
IL-2 and continuation of culture with IL-7 + IL-15) can successfully induce tumor
regression in FVBN202 transgenic mouse model of breast carcinoma upon adoptive
immunotherapy (AIT), only when combined with the depletion of endogenous
MDSCs. In this study we have introduced a novel formulation of the sequential
common gamma chain cytokines (initiation of culture with IL-7 + IL-15 followed by
the expansion with IL-2 until 6 days) for the ex vivo expansion of the autologous and
tumor-sensitized low affinity T cells derived from FVBN202 mice and further used
for AIT. This novel formulation induced differentiation of tumor-reactive CD8+ T
cells mainly towards effector and effector/memory phenotypes that were refractory
to MDSCs in vitro and in vivo. AIT by using these T cells induced rejection of
primary neu positive tumors and generated long-term memory responses against the
recall tumor challenge. Importantly, these T cells also resulted in the inhibition of
neu antigen negative relapsed tumor cells. Our findings in the present study provide
a platform for AIT of breast cancer patients.

xii

CHAPTER 1 Introduction

1.1. Cancer-Statistics and Challenges
Despite extensive ongoing cancer research and newly emerging therapeutic strategies,
cancer remains to be a devastating disease in the world. According to the American
Cancer Society report in 2009, cancer accounts for nearly one-quarter of deaths in the
United States, exceeded only by heart diseases. Worldwide, one in eight deaths is due
to cancer, exceeding the mortality rate of AIDS, malaria and tuberculosis combined.
The corresponding estimates for total cancer deaths in 2007 were 7.6 million, or about
20,000 cancer deaths a day, with 2.9 million in economically developed countries and
4.7 million in economically developing countries. By 2050, the global burden is
expected to grow to 27 million new cancer cases and 17.5 million cancer deaths.
Moreover, the direct and indirect costs of cancer are extensive (1) and are a financial
burden for the society. In women, breast cancer is the second most prevalent fatal
cancer exceeded by lung cancer and followed by colon and rectum cancer.
1.2. Breast Cancer and Importance of ErbB Family of Receptor Tyrosine KinaseStructure and Function in Cancer InitiationBreast cancer is the most frequently occurring cancer in women in the United States,
with an overall risk of developing invasive breast cancer 1 in 8 (2, 3). Her-2/neu
1

(human epidermal growth factor receptor 2), is an onco-protein that upon activation
triggers intracellular signaling events, crucial for cell growth, proliferation,
differentiation and survival (4). It has been reported that the Her-2/neu proto-oncogene
is amplified in 25-30% of human primary breast cancers (5), which has been associated
with tumor aggressiveness and unfavorable clinical prognosis (6). Overexpression of
Her-2/neu is evident by the gene amplification as well as protein overexpression. A
variety of carcinomas including ovarian, prostate, lung, liver, kidney, bladder, and
gastric cancer also overexpress Her-2/neu (4). Therefore, effective therapeutic
formulation that targets Her-2/neu may be applicable to all types of carcinomas with
the overexpression of Her-2/neu. A correlation was established between Her-2/neu
gene amplification/Her-2/neu receptor overexpression and other positive indications of
tumor progression such as tumor size, absence of hormone receptor expression,
aneuploidy and proliferation index, all of which are associated with poor prognosis (79).
Her-2/neu or rat neu with 89% homology to human Her-2/neu (10) is a member of the
epidermal growth factor receptor (EGFR) family, also known as ErbB family of
tyrosine kinase receptors. The Epidermal Growth Factor (EGF) is known to stimulate
epidermal proliferation and eventual keratinization. The EGFR was discovered in 1975
as a specific target for epidermal growth factor (11, 12), and it is the first cell surface
receptor known to be linked directly to cancer. The EGFR family encompasses 4
members, ErbB1 (EGFR itself), ErbB2 (also known as Her-2/neu), ErbB3 and ErbB4
(13). All members of this family are structurally related and composed of closely related
2

single chain modular glycoproteins with a heavily glycosylated extracellular ligand
binding region (~620 residues), a single transmembrane domain (~23 residues) and an
internal tyrosine kinase domain (~260 residues) that is flanked by juxtamembrane (~40
residues) and a C terminal (~232 residues) regulatory regions. The extracellular domain
(ECD) is composed of 2 homologous large domains and 2 cysteine rich domains (13).
Sub-domains I (ECDI), located most distally from the cell membrane, together with
sub-domain III (ECDIII), are the homologous members of the leucine rich repeat family
and participate in binding to extracellular ligands (13-17). Sub-domains II (ECDII) and
IV (ECDIV) are cysteine rich and ECDII acts as a dimerization arm. In the presence of
ligands ECDII is exposed and facilitate heterodimerization with the ECDII of other
ErbB molecules (13-15). In the absence of the ligands the ErbB molecules assume a
“tethered” structure, and during this orientation ECDIV interacts with ECDII thereby
blocking its dimerization interface (13-15). Her-2/neu is unique among the family with
its ECDII dimerization arm being constitutively exposed. This structural peculiarity
makes it accessible to other ErbB family members for heterodimer formation (18). In
fact, it is the most highly preferred heterodimerization partner of the other ligand bound
family members. Her-2/neu has no known direct activating ligand, which provides a
satisfying explanation for the unique biological properties of this orphan receptor, since
ligand binding to ECDI and ECDIII facilitates a conformational change that exposes
ECDII in other ErbB molecules, ultimately resulting in a unique dimerization that is
purely receptor mediated (13, 14, 16, 17). The receptor molecules of EGFR family in
general, in the ligand-induced dimer conformation become tyrosine autophosphorylated
3

in trans. The resulting phosphotyrosine recruits the SH2 domain of multiple
downstream signaling molecules thus initiating an array of intracellular signaling
pathways (13). In the case of Her-2/neu, overexpression of the receptor alone favors
increased dimerization with other ErbB family members or its homodimerization,
thereby triggering signaling cascades that ultimately result in uncontrolled proliferation
and cell survival (14, 19). The intracellular signaling pathway of Her-2/neu is thought to
involve ras-MAPK, MAPK independent S-6 kinase and phospholipase c-gamma
signaling pathways (7). The above mentioned observations explain the reasons why
overexpression of Her-2/neu can cause cell transformation. Several cancer therapeutic
strategies targeting Her-2/neu have been introduced in the past few years namely
monoclonal antibody therapy, tyrosine kinase inhibitors, and vaccines. A monoclonal
antibody Trastuzumab (Herceptin®) that was approved by the Food and Drug
Administration (FDA) recognizes ECDIV of Her-2/neu and is effective against 30% of
the Her-2/neu positive breast cancers, though majority of patients develop resistance
within 9 months of treatment. Trastuzumab is not effective against Her-2/neu
overexpressing ovarian cancers, therefore, other monocolonal antibodies that target
different sub-domains of the Her-2/neu ECD are being developed. Among these,
Pertuzumab recognizes ECDII and has been shown to be effective against Her-2/neu
overexpression breast and ovarian cancer in clinical trials (20).
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Figure 1A: Domain organization of a typical member of the Epidermal Growth
Factor Receptor Family.
The receptor is composed of an extracellular region, a transmembrane domain and a
tyrosine kinase domain. The tyrosine kinase domain is flanked by a juxtamembrane
region and a regulatory C-terminal region. The extracellular domain (ECD) is composed
of four sub domains, namely Domain I (ECDI), Domain II (ECDII), Domain III
(ECDIII) and Domain IV (ECDIV).

Figure 1B: The structure and dimerization pattern of ErbB molecule
The top panel shows ErbB2 (left) with a constitutively exposed dimerization arm
(ECDII) even in absence of ligand whereas ErbB1, 3 and 4 adopt the “tethered”
conformation in absence of the ligand (centre). Upon ligand binding (right) ErbB1, 3
and 4 acquire a conformational change that exposes the dimerization arm for binding.
The middle panel shows that ErbB2 molecule exhibiting a fixed conformation
resembling a ligand activated state of EGFR and ErbB3 molecules. The bottom panel
shows ligand binding to ErbB receptors which induces the homo- and heterodimerization and subsequent activation of the intrinsic kinase domain which results in
phosphorylation of specific tyrosine residues within the cytoplasmic tail. These
phosphorylated residues serve as docking sites for a range of proteins, the recruitment
of which leads to the activation of intracellular signal pathways.
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Figure 1A

Burgess, A. W., H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, M. A. Lemmon, M. X.
Sliwkowski, C. W. Ward, and S. Yokoyama. An open-and- shut case? Recent insights into the activation of
EGF/ErbB receptors. Mol. Cell 12(3):541-552, 2003.
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Figure 1B

Hynes,N.E. and H.A.Lane. ERBB receptors and cancer. The complexity of targeted inhibitors.
Nat.Rev.Cancer 5(5):341-354, 2005.
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1.3. Mouse Model
The FVBN202 mouse model of neu overexpressing spontaneous mammary carcinoma
provides a clinically relevant model for investigating the immunotherapy of Her-2/neu
positive breast cancer. These mice develop spontaneous mammary tumors within 4-12
months of age as a result of overexpression of the unactivated form of rat neu oncogene
in their mammary glands under the control of the mouse mammary tumor virus
(MMTV)

promoter

(21).

The MMTV/unactivated

neu

is

isogenic to

the

MMTV/activated neu except for the absence of the activating mutation in the
transmembrane domain and the presence of a SalI restriction endonuclaese site between
the neu cDNA and SV40 polyadenylation splicing signals.
FVBN202 mice develop premalignant mammary hyperplasia similar to ductal
carcinoma in situ (DCIS) prior to the development of spontaneous carcinoma within
1.5-2 months of age. Spontaneously arising mammary tumors are harvested from these
mice and processed in the laboratory to establish neu + mouse mammary carcinoma cell
lines, referred to as MMC. The endogenous overexpression of neu oncogene in these
transgenic mice makes them immunologically tolerant to neu oncoproteins. This makes
the animal model clinically relevant, mimicking the normal condition of human breast
cancer, where malignancy develops from “self” tissues thereby escaping the body’s own
immune system. The T cells harvested from these mice are of low affinity for the neu
tumor antigen. On the contrary, wild type FVB mice do not express the rat neu
oncogene, so the immune system of these mice can exhibit robust responses, when the
animals are inoculated with neu+ mouse mammary carcinoma (MMC) tumors derived
8

from spontaneous mammary tumor of FVBN202 mice. The animals can subsequently
reject MMC, because of harboring the neu specific T cells that express high affinity
receptors for the neu antigen. It has been reported previously, that FVBN202 mice
show an increased level of myeloid-derived suppressor cells (MDSCs) during the
initiation and establishment of spontaneous breast carcinoma (22). Figure 1C shows the
correlation of the increased abundance of CD11b+Gr1+ MDSCs along with the
progression and establishment of spontaneous breast carcinoma. Slides show the section
of the normal mammary duct followed by the gradual proliferation of the epithelial
layer during premalignant atypical ductal hyperplasia (ADH) and finally with the
establishment of malignant breast tumor. Uncontrolled proliferation of the epithelial
layer coincided with the increased level of MDSCs (22).

9

Figure 1C: Increased level of MDSCs along with the progression and
establishment of breast carcinoma
The figure shows an increased CD11b+Gr1+ MDSCs along with the gradual
progression and establishment of mammary carcinoma. Starting from the normal level
in FVBN202 mice with healthy mammary epithelial ducts, the MDSCs show consistent
increase during the atypical ductal hyperplasia (ADH) and invasive breast cancer.
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Figure 1C

Kmieciak et al. “Danger signals and nonself entity of tumor antigen are both required for eliciting effective
immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.”. l Cancer
Immunol Immunother. 57: 1391-1398, 2008.
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1.4. Myeloid -Derived Suppressor Cells (MDSCs) – How do they abrogate antitumor immune responses in vivo
Tumor development is often accompanied by a peculiar alteration of hematopoesis that
leads to a progressive accumulation of myeloid cells in bone marrow, blood, spleen and
at the tumor site. These cells share the markers CD11b and Gr1 and their accumulation
correlates with the inhibition of T cell responses to antigenic stimulation both in vivo
and in vitro. CD11b+ Gr1+ cells are heterogenous and are commonly known as myeloid
derived suppressor cells (MDSCs). The abundance of this cell population is correlated
with many types of cancer namely murine colon carcinoma MCA-26, Lewis lung
carcinoma, highly metastatic breast carcinoma, 4T1, neu+ breast carcinoma

and

melanoma (B16) (23, 24-27). Increased abundance of circulating MDSCs correlates
with clinical cancer stage and metastatic burden of breast cancer. Stage IV patients with
extensive metastatic tumor burden had the highest percentage and absolute number of
MDSCs (28). Increased abundance of MDSCs during tumor progression is associated
with enhanced myelopoesis, because soluble factors secreted from tumors including
GM-CSF and VEGF are known to stimulate myelopoesis or block the maturation of
hematopoetic progenitor cells, respectively (23, 29). It is still not clear which signaling
pathway is specifically involved in the induction of MDSCs. A number of pathways
including STAT1, STAT3, c-kit ligand/ receptor have been suggested to be responsible
for induction of MDSCs. The heterogenous population of MDSCs characterized by
CD11b+Gr1+ actually represents a macropopulation. Different epitopes of the Gr1
molecules have been identified, namely Ly6G and Ly6C in different subsets of MDSCs
12

characterized by different functional attributes (25, 30, 31). The Ly6 family members
are cysteine rich molecules that are glycosyl phosphatidylinositol (GPI)-anchored to the
cell surface; it has recently been reported that expression of Ly6G represents a
granulocytic phenotype whereas Ly6C correlates with a monocytic phenotype. The
mononuclear cell MDSCs are akin to inflammatory monocytes whereas polymorpho
nuclear (PMN) MDSCs are closer to immature neutrophils. Blocking IFN-γ or
disrupting STAT1 impaired suppression by the former while IFN-γ was required for
suppression by PMN MDSCs (25, 30). Recent reports reveal that the monocytic
phenotype contributes to the suppressive function of MDSCs (32, 33).
The exact mechanism of T cell suppression by MDSCs remains elusive. It has been
reported that MDSCs can acquire endothelial cell property in tumor microenvironment
and supports angiogenesis, thereby favoring tumor growth while ignoring the immune
sentinels. They are also known to cause apoptotic death of CD8+ T cells (34).
Gabrilovich et al. have shown antigen specific contact-dependant suppression of T cells
by MDSCs. They showed that Gr1+ cells express myeloid cell marker and MHC class I
but lack MHC class II and do not affect T cell proliferation or IL-2 production induced
by Concanavalin A or by MHC class II but they do exert a detrimental effect on the
number of IFN-γ producing CD8+ T cells in response to specific peptides presented by
MHC class I (35). Other reports reveal that MDSCs may work through downregulation
of T cell receptor (TCR) zeta chain and can cause dysfunction of T cells described in
cancer, infectious diseases and autoimmune disorders (36). Morales et al. also reported
that MDSCs inhibit T cell activation in FVBN202 mice in a contact-dependent manner
13

(37). Another probable mode of suppression by MDSCs has been argued to be
dependent on the production of nitric oxide (NO) as well as other soluble factors. It has
been shown that suppression is due to the impairment of IL-2 receptor signaling
pathways mediated by and requires NO, which is secreted by MDSCs in response to
signals from activated T cells, including IFN-γ and a contact-dependent stimulus (38).
Gabrilovich et al. proposed that antigen specific CD8+ T cell tolerance is one of the
major mechanisms of tumor escape. They have shown that the tolerance is induced by
MDSCs. They have found that MDSCs directly disrupt the binding of the specific
peptide-MHC complex dimers via nitration of tyrosines within the TCR/CD8 complex,
which results in the inability of CD8+ T cells to respond to the specific peptides.
Nitration of the TCR by MDSCs is thought to be induced by hyperproduction of
reactive oxygen species (ROS) and peroxinitrite during cell-cell contact (39). Some
reports showed inhibitory effect of arginase I produced by MDSCs. Arginase I
metabolizes L-arginine to urea and ornithine whereas nitric oxide synthase 2 converts it
to citrulline and NO. Depletion of L-arginin by any one of these pathways results in T
cell dysfunction. High arginase activity is reported in lung and colon cancer (23, 27).
The same group confirms that MDSC-mediated down regulation of L-selectin to be a
major cause of T cell suppression as T cells must express L-selectin (high) in order to
home to lymph nodes and sites of inflammation where they encounter antigen and are
activated. This downregulation perturbs T cell trafficking patterns thereby inhibiting T
cell activation (40, 41). Although several groups have proposed various mechanisms of
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suppression by MDSCs, the exact mode of action remains unclear. It is likely that
different mechanisms of suppression exist in different cancer models.
1.5. Cancer Therapeutics- An overview of adoptive immunotherapy
Paul Ehrlich was one of the first to conceive the idea that the immune system could
repress a potentially “overwhelming frequency” of carcinomas arising from ‘self’
tissues. To a large extent, the revisiting of Ehrlich’s proposal had to await the
maturation of the developing field of Immunology. In 1950, the work of Medawar and
colleagues clarified the critical role of cellular components of immunity in mediating
allograft rejection. This work cast doubt on data that were used to argue for the
existence of tumor antigen. Although it was generally accepted that the immune
response was capable of recognizing and destroying transplanted tumors derived from
outbred strain of mice, it soon became clear that the underlying mechanism was that of
allograft rejection rather than tumor specific rejections. With the introduction of inbred
strains of mice, it became clear that the syngeneic tumor transplant can be
immunologically distinguishable from the normal “self” entities. The endogenous
immune system components recognizing and abrogating the nascent transformed cells
were described as “immunosurveillance” by Sir Macfarlane Burnet and Lewis Thomas.
They speculated that lymphocytes acted as sentinels in recognizing and eliminating
continuously arising nascent transformed cells and that tumor cell specific neoantigens
could provoke an effective immunologic reaction that would eliminate cancer
development (42, 43).
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Along this line of thought Dighe et al. reported that endogenous production of IFN-γ
can protect the host against growth of transplanted tumors along with the formation of
the primary chemically induced and spontaneous tumors (43). It was shown that
administration of the neutralizing mAbs against IFN-γ into mice transplanted with Meth
A tumors blocked LPS-induced tumor rejection. It was also proved that transplanted
fibrosarcomas grew faster in mice treated with IFN-γ blocking antibodies (43, 44).
Early studies identified perforin (Prf) as a critical cytolytic molecule in the primary
host’s anti-tumor responses. After challenge with Meth A tumors, Prf-/- mice formed 23 times more tumors than wild type mice. In addition 50% of aging Prf-/- C57BL/6
mice developed spontaneous disseminated lymphomas as compared to 1/16 wild type
mice (42, 43).
Availability of immune deficient mice allowed testing of tumor immunosurveillance
hypothesis. Genetically manipulated mice lacking recombinase activating gene, RAG-2
or its obligate partner RAG-1 cannot somatically rearrange lymphocyte antigen
receptors, and thus cannot produce peripheral αβ T cells, B cells, NKT cells or γδ T
cells. RAG-2 expression is limited to the cells of lymphoid system; therefore RAG-2-/mice provide an appropriate model to study the effect of host cell lymphocyte
deficiency on tumor development. It has been shown that following subcutaneous
injection of Meth A tumor cells, 129/ SvEv RAG-2-/- mice developed tumor at the
injection site faster than the wild type control group. NK and NKT cells also participate
in cancer immunoserveillance. C57BL/6 mice, depleted of both natural killer and
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natural killer T cells using the anti-NK1.1 mAb, were two to three times more
susceptible to Meth A-induced tumorigenesis (43).
Presence of tumor immunosurveillance supported by the above-mentioned evidences
provides a platform for immunotherapy of cancers. This suggests that cancer patients or
tumor-bearing animals harbor tumor-reactive T cells that, if expanded ex vivo, can result
in tumor regression upon adoptive T cell immunotherapy (AIT) (45). This method has
gained some success in melanoma and in the treatment of patients with cancers
expressing viral antigen such as Epstein Barr Virus (46).
T cells for AIT can be harvested from various sites from the tumor-bearing hosts,
including peripheral blood, tumor biopsies, resected lymph nodes, malignant effusions
and spleens. Obtaining T cells from the peripheral blood may be easier, but higher
frequency of tumor reactive T cells can be found in tumor biopsies (tumor-infiltrating
lymphocytes, TIL) (47). However, harvesting sufficient number of TIL can be difficult,
though this approach has been used successfully in patients with melanoma (47).
Successful AIT depends on the type of T cells transferred, their effector functions,
ability to reach tumor location and the ability of the cells to overcome any tolerance or
immune suppression in the host. The immunogenic potential of the tumor antigen, size
and location of tumor, and the regimen used for of the ex vivo expansion of autologous
T cells determine efficacy of the therapy. Three major criteria for successful AIT are
(48, 49):
•

Sufficient numbers of T cells with high reactivity against the tumor in vivo

•

Trafficking of T cells to and infiltrating in the tumor stroma
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•

Activation at the tumor site to manifest appropriate effector mechanisms such as
direct lysis or cytokine secretion capable of tumor destruction

It has been shown that efficacy of AIT depends on T cell phenotype. Terminally
differentiated CD8+ T cells were nearly 100- fold less effective in vivo on a per cell
basis than T cells at an early stage of differentiation. Less differentiated T cells have
high proliferation potential and are less prone to apoptosis than more differentiated cells
and have a higher ability to respond to homeostatic cytokines as they express receptors
IL-7 Rα chain (45). For an effective and successful AIT, T cells should possess effector
functions and the ability to generate memory responses (50). The major cytotoxic
function of the CD8+ T cells demands direct cellular contact with the target cells. To
induce the tumor specific cell death, the effector CD8+ T cells should reach the tumor
site. This potential extravasations’ capacity depends on their ability to adhere to
endothelial walls while withstanding shear stresses exerted by flowing blood. The
tethering and rolling mechanism is governed by the selectin family (51). It has been
reported that loss of expression of the lymphoid homing molecules such as CD62L or
CCR7 and acquisition of CD44 expression can be associated with increased anti-tumor
effects of adoptively transferred T cells (45). Moreover, expression of CD44 has been
shown to be the most potent stimulator of Fas ligand expression on human T cells (52)
which in turn may induce apoptosis in Fas positive target cells.
Previous preclinical studies indicated that immune ablation is an effective
preconditioning regimen that can increase T cell responses after adoptive
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immunotherapy, as lymphodepletion increases the efficacy of transferred T cells.
Transfer of small numbers of antigen-specific T cells into a lymphopenic host results in
the expansion and activation of the transferred T cell population, known as homeostatic
proliferation. Adoptively transferred antigen-specific T cells represent a small portion
of the total T cell population residing in the host. Host mediated inhibitions of the
proliferation of adoptively transferred T cells might involve direct cellular contact or
competition between transferred and endogenous host T cells for a limited amount of
resources such as cytokines that are required to support transferred T cells homeostasis.
This is known as the “cytokine sink” effect. Lymphodepletion can overcome cytokine
sink effects and also decrease the competition at the surface of antigen-bearing antigen
presenting cells (APC). Gattitoni et al. reported that a lymphopenic environment
enables tumor-reactive T cells to destroy large tumors more effectively (45). The same
group has also reported that though lymphodepletion reduces the number of APC in
vivo, it is also linked to the increasing the number of mature activated APCs which can
facilitate the activation of transferred cells (45). To create a lymphopenic host
environment, several methods including total body irradiation, genetic alteration and
chemotherapy can be applied. In this study we have used cyclophosphamide (CYP) for
lymphodepletion. CYP is a synthetic antineoplastic drug and an alkylating agent that
interferes with the growth of rapidly proliferating cells (53). CYP is also known to
remove tumor- induced suppressor T cells. The above discussion clearly depicts that the
elimination of the host immune suppressive environment is a primary pre-requisite for
effective AIT. The MDSCs are known to be a major contributor to the tumor associated
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immune suppression in a number of carcinomas. Tumor cells secrete immune
suppressive cytokines such as IL-10, TGFβ and

VEGF. Tumors express

immunosuppressive enzyme indoleamine 2,3-dioxygenase which is involved in
tryptophan metabolism. This enzyme appears to exert its suppressive effect through
depletion of tryptophan and production of anti- inflammatory tryptophan metabolites
(47). All these suppressive elements which can abrogate T cell functions should be
eliminated prior to AIT.
Though several ways have been introduced to circumvent these endogenous MDSCs,
none of them has achieved complete success. The abundance of these suppressive cells
in the tumor microenvironment remains a critical challenge for successful AIT.
1.6. Bryosatin-1/Ionomycin treatment and application of novel cytokine
formulation for the ex vivo expansion of tumor-reactive T cells prior to AIT
Bryostatin-1 belongs to a class of macrocyclic lactones derived from the marine
bryozoans, Bugula neritina. It binds to the regulatory domain of Protein Kinase C
(PKC) and governs its activation as well as inhibition. Short-term treatment with
Bryostatin-1 activates PKC while long exposure may have a detrimental effect (37).
Ionomycin is a calcium ionophore that increases the intracellular Ca2+ concentration,
which acts as a second messenger in various signaling cascades (54). The treatment
with Bryostatin-1 and Ionomycin (B/I) induces selective activation of tumor-specific T
cells without the need for identification of tumor antigen (55). Exposure to both
bryostatin-1 and ionomycin (B/I) mimics signaling through the CD3/TCR complex and
leads to activation and proliferation of effector T cells (55).
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Adoptive immunotherapy of cancer patients utilizes the ex vivo expansion of tumorreactive T cells by using cytokines or other pharmacological agents to generate a large
number of such immune effector cells (56). Among the common gamma chain (γc)
cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) mainly IL-2, IL-7, IL-15, and/or IL-21
have been used to improve the efficacy of AIT. The common γ chain component of the
receptors of these cytokines stimulates MAP kinase and PI3 kinase pathways that result
in anti-apoptotic and mitogenic signals (57).
The endogenous naïve T cells characterized by the presence of CD45RA can
differentiate into quiescent memory cells bearing the characteristic of CD45RO surface
protein and effector cells when first encounter the antigen. The quiescent memory cells
may also arise from the differentiation of effector cells following activation. There are
two types of memory T cells. Central/memory T cells are characterized by the
expression of CD44 and CD62Lhigh whereas effector/memory T cells are characterized
by the expression of CD44 and CD62Llow. The latter mature rapidly into effector cells
after re-stimulation and secrete large amounts of IFN-γ or IL-4 (58). The ex vivo
manipulations of T cells during the expansion can preferentially support the survival
and proliferation of these various effector and memory phenotypes of T cells.
IL-2 is the major T cell growth factor cytokine that is produced by activated T cells.
The IL-2 receptor is expressed by activated T cells, activated B cells and NK cells. The
receptor comprises three polypeptide subunits: IL-2 receptor α chain (CD25), IL-2Rβ
chain (CD122) and IL-2Rγ chain (CD132). IL-2Rβ and γ chains participate in signal
transduction whereas the α chain augments binding affinity for IL-2 (55). IL-2 is known
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to cause activation-induced cell death (AICD), and it preferentially supports
differentiation of CD8+ T cells towards effector and effector/memory phenotypes by
down regulation of the lymph node homing receptors CD62L (59, 55). Culture of B/I
activated human T cells from healthy donors with IL-2 ex vivo resulted in the de novo
generation of the CD4+CD25+ FoxP3+ T cells without any detectable suppressive
function (60).
IL-7 is the hematopoietic growth factor cytokines which is secreted by the stromal cells,
epithelial cells and fibroblasts but is not produced by lymphocytes. The receptor for this
cytokine is expressed by T cells, pre-B cells and dendritic cells (DCs). IL-7 receptor
consists of an α chain (CD127) and shares common γ chain (CD132) with IL-2
receptor. IL-7 is crucial for the survival and homeostatic expansion of naïve and
memory CD8+ T cells. Injection of IL-7 results in the expansion of both CD4+ and
CD8+ T cells as well as the relative reduction of CD4+ Tregs (55, 61).
IL-15 is produced by monocytes, dendritic cells (DCs) and epithelial cells. IL-15
receptor consists of an α subunit and shares common β and γ subunits with the IL-2
receptor. IL-15 receptor is expressed by T cells and NK cells. IL-15 induces expression
of anti-apoptotic Bcl-2 as well as inhibition of pro -apoptotic Bim in CD8+ T cells
expressing the receptors for IL-7, thereby decreasing AICD in those specific subsets of
CD8+ T cells (62). IL-15 is known to favor the differentiation and proliferation of the
CD8+ central memory subset of T cells. While IL-7 and IL-15 are responsible for
supporting the primary memory CD8+ T cells, only IL-15 is known to support the
secondary memory phenotypes (63). This cytokine is also reported to render T
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effector/memory cells refractory to the suppressive function of Tregs via activation of
the PI3 kinase cascades but does not involve the rescue of those T cells from apoptosis
(64). IL-15-expanded CD8+ T cells display only effector functions in vitro but are
highly effective in vivo. This is likely because the IL-15-induced differentiation of T
central/memory subsets are responsible for generating prolonged memory responses in
vivo whereas the effector T cells undergo apoptosis after several cycles of proliferation
or cytolytic function against tumor in vitro (55).
In this study we have aimed to introduce a novel cytokine regimen for the ex vivo
expansion of T cells that can render the T cells refractory to the inhibitory effects of
MDSCs and generate long-term memory responses following AIT.
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CHAPTER 2 Materials and Methods

Mouse model
FVBN202 transgenic female mice (Charles River Laboratories) were used between 6 to
8 weeks of age throughout these studies. These mice overexpress an unactivated rat neu
transgene under the regulation of MMTV promoter (21). These mice develop
premalignant mammary hyperplasia similar to ductal carcinoma in situ (DCIS) prior to
the development of spontaneous carcinoma (22). The studies have been reviewed and
approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia
Commonwealth University. The mice were sacrificed before they attained a tumor
volume of 2000mm³.
Tumor cell lines
The MMC cell line was established from a spontaneous tumor harvested from an
FVBN202 transgenic mouse as described previously (65). The antigen negative variant
(ANV) cell line, characterized by a loss of neu expression, was derived from a relapsed
MMC tumor in the FVB strain as previously described (65). Both cell lines were
maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Mice
were challenged with 3-5x106 tumor cells by subcutaneous (s.c.) inoculation wherever
indicated in this study.
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Expansion of effector T cells derived from FVBN202 mice
Female FVBN202 mice were inoculated with 4X106 MMC cells and the splenocytes
were harvested after 10-21 days. Splenocytes (106cells/ml) were stimulated in a warmed
complete medium containing 15% FBS with Bryostatin-1 (5nM) and Ionomycin
(10nM) along with 80U/ml of IL-2 (Peprotech) for 16 hours. Cells were washed three
times and cultured at 106 cells/ml in complete medium (RPMI-1640 supplemented with
100U/ml of penicillin, 100µg/ml streptomycin, 10% FBS, glutamine and βmercaptoethanol) with 10-20ng/ml of IL-7 and IL-15 (Peprotech). After 24 hours
20U/ml of IL-2 was added to the medium. On the next day cells were washed three
times and cultured (106cells/ml) in complete medium with 40U/ml of IL-2. Cells were
counted and cultured at 106cells/ml in complete medium with 40U/ml of IL-2 every
other day for a total of 6 days.
Adoptive immunotherapy
24 hours prior to adoptive immunotherapy (AIT), FVBN202 mice were treated with
Cyclophosphamide (CYP, 100mg/Kg) by intraperitoneal (i.p) injection in order to
induce lymphopenia. Mice were challenged with 3X106 MMC cells (s.c.) and then
received 70X106 ex vivo expanded T cells by tail vein (i.v) injection later on the same
day. Tumor growth was monitored by digital calipers and tumor volumes were
calculated by: Volume (v) = [L (length) x W (width) ²]/2. Blood was collected from the
orbital sinus to determine the level of circulating CD11b+Gr1+ cells by flow cytometry.
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At the termination of the experiments, splenocytes were harvested and stained using the
appropriate antibodies for several surface markers and internal molecules.
Cytotoxicity assay
Freshly harvested lymphocytes or ex vivo expanded T cells were cultured with MMC or
with CFSE labeled ANV at 10:1 ratio, in 3 ml complete medium (RPMI-1640
supplemented with 100U/ml of penicillin, 100µg/ml streptomycin, 10% FBS, glutamine
and β- mercaptoethanol) and 20U/ml of IL-2 (Peprotech) in 6 well culture dishes. Prior
to co-culture, ANV cells were stained with CFSE, to gate out the CFSE+neu- ANV
population for estimating viability of the tumor cells. After 48 hours, MMC cells were
harvested and stained for neu (anti-c-Erb2/c–Neu, Clone-4, Calbiochem) along with
FITC anti mouse IgG, Annexin V-PE and Propidium Iodide (PI) according to
manufacturer’s protocol (BD Pharmingen). In case of ANV, neu staining was omitted.
Flow cytometry was used to analyze the viability of neu positive cells.
CFSE staining
5X10⁶ ANV cells were resuspended in 5 ml of HBSS and spun for 10 minutes at 1200
rpm at 4⁰C. The HBSS was discarded and cells were stained with 1.5µM of CFSE in 1
ml HBSS for 5 minutes at room temperature in the dark. After incubation cells were
washed with 1 ml of FBS, followed by three more washes with HBSS+10% FBS.
Finally cells were resuspended in complete media and desired numbers of cells were
used for cytotoxicity assay.

26

Flow cytometry
Flow cytometry analyses were performed as standardized by our laboratory. The
freshly isolated spleens were homogenized into a single cell suspension and red blood
cells were lysed using 1X ACK (NH4Cl, KHCO3, EDTA.Na2.2H2O) lysis buffer for 6
minutes at room temperature. Cells were washed with 2 volumes of RPMI1640
supplemented with 10% FBS, and then resuspended in Flow Cytometry cell staining
buffer (1X PBS with 1 % FBS and 0.1% of sodium azide). Cells were counted and
aliquoted into each sample tube (10⁶ cells/tube). The splenocytes were used either
freshly isolated from the mice or after co-culturing for 24 hours with and without
MMC; or after a 6-day expansion with a special cytokines regimen. Non-specific
binding to Fc receptors was blocked with anti-CD16/32 antibody (Biolegend, San
Diego, CA) for 20 minutes on ice. Cells were stained with surface antibodies namely
against CD4 (GK1.5), CD8 (53-6.7), CD3 (145-2C11), CD69 (H1.2F3), CD11B
(M1/70), Gr1 (RB6-8C5), Ly6G (1A8), CD62L (MEL-4) and CD44 (IM-7) and
incubated on ice in the dark for 20 min. All antibodies were used at the manufacture’s
recommended concentration. Cells were washed twice and fixed with 1%
paraformaldehyde. For internal staining with anti-perforin (eBioOMAK-D) antibody
(eBioscience), FoxP3 Fix/ Perm Buffer system was used according to the
manufacturer’s protocol (Biolegend, San Diego, CA). For Granzyme-B and IFN-γ
(XMG1.2) (eBioscience) staining, cells already stained for extracellular molecules were
fixed with 2.5% paraformaldehyde for 10 min on ice, permeabilized by washing with
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1ml and then with 2ml of 0.1% saponin buffer, and stained with internal antibodies for
30 minute on ice in the dark. Especially for IFN-γ staining, transport blocker
(Monensin) was added to the growing cell culture medium 4 hours prior to staining.
Lastly, cells were washed twice with normal cell staining buffer and resuspended in 500
µl of the same. For Annexin V staining, after cells were stained for respective surface
markers followed by a wash with Flow Cytometry cell staining buffer, they were
washed again with 1X Annexin V buffer (BD Pharmingen) and the Annexin V staining
protocol was followed according to manufacturer’s recommended protocol. Samples
were run on a Beckman Coulter FC 500 and analyzed using Summit version 4.3
software.
IFN-γ ELISA
Tumor-sensitized freshly isolated effector lymphocytes or ex vivo expanded T cells
were cultured in complete medium at a 10:1 ratio with irradiated MMC cells for 24
hours. Supernatants were collected and stored at-80⁰C until used. IFN-γ was detected
using a Mouse IFN-γ ELISA set (BD Pharmingen) according to the manufacture’s
protocol.
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Protein ELISA
ELISA was performed as previously described by our group (37). Blood was collected
from experimental animals from the retro-orbital sinus, allowed to sit at room
temperature for 10 minutes, and then spun for 10 minutes at 10,000 rpm. Serum was
harvested and stored at -80⁰C until used. For measuring the antibody response against
neu, 96 well plates were coated with 10 µg/ml of the ECDII and incubated overnight at
4⁰ C. Plates were washed with PBS+0.05% Tween-20 and blocked with 2% skim milk
for one hour. After washing, 5 and 50-fold serial dilutions of the sera were added
(100µl/well) and incubated for 2 hours at room temperature. Horse-radish-peroxidase
(HRP)-conjugated anti-mouse IgG1 was added at a 1:2000 dilution for 1 hour. Plates
were washed and reactions developed by adding 100µl/well of the TMB Microwell
peroxidase substrate (Kierkegaard & Perry). The reaction was stopped with 2M H2S04,
and the O.D. read at 450 nm. Mean antibody titers were calculated.
Isolation of Myeloid-Derived Suppressor Cells (MDSCs) in vitro
MDSCs were isolated from tumor-bearing FVBN202 animals using an EasySep PE
selection kit from StemCell Technologies following manufacturer’s protocol. For the
isolation purpose, cells were stained with Gr1-PE antibody (Biolegends, San Diego,
CA).

29

Suppression assay
In suppression assay T cells were cultured in the presence of isolated Gr1-PE labeled
MDSCs in a ratio of 2:1. Such mixed cell population was co-cultured with MMC at a
ratio of 10:1:5 of Effector:Target:MDSC cells. Flow cytometry analysis was performed
to examine various surface markers and internal molecules expressed by T cells upon
stimulation/suppression. Supernatants from these co-cultures were collected for IFN-γ
ELISA. For cytotoxicity assay, the cell population (T+MMC+MDSC) was stained with
purified mouse monoclonal antibody against rat neu (anti-c-Erb2/c–Neu, Clone-4,
Calbiochem) along with FITC- anti mouse IgG, Annexin V-PE and Propidium Iodide
(PI) according to manufacturer’s protocol (BD Pharmingen).
Tumor challenge studies
FVBN202 mice received MMC inoculations earlier the same day prior to receiving
AIT. After successful rejection of primary tumors, they were re-challenged for second
(n=3) and third (n=1) time on day 23 and day 61, respectively, with 5 X10⁶ MMC by
s.c. inoculation. The recipients were also challenged with 4X10⁶ ANV (n=2) on day 50.
Subsequent tumor inoculation was done on the contralateral side. Tumor growth was
monitored at regular intervals.
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Statistical analysis
Graphical data are presented as averages with standard errors. Statistical comparisons
between groups were made using Student’s T test with P< 0.05 being statistically
significant.
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CHAPTER 3 Study Rationale and Results

Study Rationale
Our laboratory has had a longstanding interest in developing an effective means of
treating neu positive mammary tumors by using tumor-specific T cells. The FVBN202
mouse model is clinically relevant for investigating adoptive immunotherapy (AIT)
because of endogenous expression of rat neu oncoprotein. These transgenic mice
develop atypical ductal hyperplasia (ADH) preceding the initiation and establishment of
spontaneous breast carcinoma (21). Our laboratory has already shown ADH coincided
with elevated levels of MDSCs in FVBN202 mice, which in turn resulted in the failure
of AIT against mammary carcinoma (22, 37). Figure 1C shows the correlation of the
increased abundance of CD11b+Gr1+ MDSCs along with the progression and
establishment of spontaneous breast carcinoma. Uncontrolled proliferation of the
epithelial layer was associated with the increased level of MDSCs (22). Previous
attempts in our laboratory to use AIT to cure neu+ tumors in FVBN202 mice have
proven unsuccessful, despite the fact that highly active effector T cells were obtained
from wild type FVB mice that could successfully reject the neu+ tumor challenge.
Efforts to identify the reasons lead to the understanding of the key inhibitory role of
CD11b+Gr1+ MDSCs in FVBN202 mice. Adoptive transfer of high affinity T cells
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derived from wild type FVB mice, activated with Bryostatin-1/Ionomycin (B/I) and
expanded with the alternating common gamma chain cytokines (culture of T cells with
IL-7 + IL-15 for 24 hours after the B/I activation followed by the overnight pulse with
IL-2 and continuation of the culture with IL-7 + IL-15) ex vivo resulted in tumor
rejection, only when combined with the depletion of MDSCs in vivo (37). However,
non-self source of T cells (from wild type FVB into FVBN202 mice) reduced clinical
application of the treatment. Therefore, in the present research we used autologous low
affinity T cells for the AIT of FVBN202 mice and developed an ex vivo protocol for the
expansion of these T cells which render them refractory to MDSCs. We first tested an
alternating common gamma chain cytokine protocol and then improved it into a
sequential cytokine formulation (IL-7+IL-15 followed by IL-2). We hypothesized that
initiation of culture with IL-7 and IL-15 would support the differentiation of tumorreactive memory T cells and continuation of the culture with IL-2 would result in the
induction of activation-induced cell death (AICD) in fully differentiated T cells,
rescuing early differentiated T cells from apoptosis. AIT by means of these T cells at
their early stage of differentiation would induce robust tumor rejection and protect
animals against recall tumor challenge by generating memory responses.
Alternating common gamma-chain cytokines expanded tumor-reactive T cells that
failed to overcome MDSCs in vivo following AIT
Splenic T cells were isolated from tumor-bearing female FVBN202 mice and expanded
ex

vivo

with

an

alternating

gamma
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chain

cytokine

formulation

(IL7/IL15→IL2→IL7/IL15) following B/I activation (37). This protocol resulted in a
2.6 and 4-fold expansion of splenocytes on day 7 compared to day 0 and post-B/I
activation respectively (Figure 2). The B/I activation resulted in a significantly
decreased splenocytes from 72 million to 46.94 million followed by a consistent
expansion attaining 188.3 million cells on day-7. Figure 3 shows the proportions of
CD8+ and CD4+ T cells from freshly isolated and ex vivo expanded lymphocytes.
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Figure 2: Ex vivo expansion of splenocytes with alternating (IL-7/IL-15→IL2→IL-7/IL-15) gamma chain cytokines
Spleen harvested from MMC-sensitized large tumor-bearing (tumor volume≤2000mm³)
female FVBN202 mouse was crushed and processed to yield single cell suspensions
which were subjected to a 7-day expansion with the alternating gamma chain cytokines.
Splenocytes were incubated with 5nM Bryostatin-1 and 10nM Ionomycin along with 80
U/ml of IL-2 in complete medium for 16 hours followed by expansion with IL-7/IL-15
(10ng/ml), alternating with IL-2 (40U/ml) and again with IL-7/IL-15. The figure shows
the fold increase of T lymphocytes at different time intervals during the expansion
protocol. Cell counts were determined by trypan blue exclusion.
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Figure 2
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Figure 3: Expansion of splenocytes with the alternating gamma chain cytokines
results in the expansion of CD8+ and CD4+ T cells
Spleen harvested from MMC sensitized large tumor-bearing (tumor volume≤2000mm³)
female FVBN202 mouse was crushed and processed to yield single cell suspensions
which were subjected to a 7-day expansion with alternating gamma chain cytokines.
The figure shows the percent total population of the CD8+ and CD4+ T cells before and
after the expansion with the alternating gamma chain cytokine formulation.
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Freshly isolated splenocytes contained 3.72% and 11.22% CD8+ and CD4+ T cells,
respectively. Culture with the alternating gamma chain cytokines resulted in increase in
the T cell subsets. CD8+ and CD4+ T cells expanded 9.27 and 3.48 fold, reaching
34.51% and 39.05%, respectively.
In order to determine viability (AnnexinV-/PI-) of T cells during the ex vivo expansion
flow cytometry analysis was performed. High viabilities for CD8+ and CD4+ T cells
were detected prior to expansion (Figure 4, upper panel) or following a 7-day
expansion (Figure 4. lower panel).
In order to determine phenotype distribution of T cells and the effects that ex vivo
expansion may have on the differentiation of T cells, we performed flow cytometry
analyses. Freshly isolated CD8+ T cells contained mainly central/memory and naïve
phenotypes accounting for 51.43% of central/memory (TCM: CD44+CD62Lhigh) and
30.71% of naïve (TN: CD44-CD62L+) T cells as well as 7.52% of effector phenotype
(TE:

CD44+CD62L-)

and

9.52%

of

effector/memory

phenotypes

(TEM:

CD44+CD62Llow). Freshly isolated CD4+ T cells contained mainly central/memory and
effector phenotypes accounting for 57.85% of TCM and 29.03% of TE cells as well as
8.08% of TEM and 5.61% of TN cells (Figure 5, upper panel). Ex vivo expansion with
the alternating gamma chain cytokines generated increased TE phenotypes for CD8+
(16.76%) and CD4+ (36.86%) T cells (Figure 5, lower panel). However, TCM remained
the most abundant phenotypes after the ex vivo expansion of CD8+ and CD4+ T cells
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(Figure 5, lower panel). The MFI for CD44 expression in the expanded CD8+ and
CD4+ T cells were 5.61 and 7.28, respectively.
In order to determine whether the ex vivo expansion of T cells may enrich for the tumorreactive T cells, we determined production of IFN-γ and cytotoxic function of T cells in
the presence (+) and absence (-) of MMC tumor cells at an effector:target (E:T) ratio of
10:1. Supernatants were collected after a 24-hour culture and assayed for IFN-γ by
ELISA. Figure 6 shows that freshly isolated splenocytes produced IFN-γ when
stimulated with irradiated MMC in vitro (3580.5 pg/ml; p= 0.0000005). Importantly,
the ex vivo expanded T cells showed significantly higher production of tumor-induced
IFN-γ than freshly isolated T cells (8.2 fold; 29400 pg/ml p = 0.036).
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Figure 4: Ex vivo expansion of T cells with the alternating gamma chain cytokine
formulation supports maintenance of highly viable lymphocyte population
Spleen harvested from MMC sensitized large tumor-bearing (tumor volume≤2000mm³)
female FVBN202 mouse was crushed and processed to yield single cell suspensions
which were subjected to a 7-day expansion with alternating gamma chain cytokines.
The cells were gated on CD8+ or CD4+ cells and analyzed for AnnexinV and PI.
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Figure 5: Ex vivo expansion of T cells with the alternating gamma chain cytokines
supports effector (TE) and central/memory (TCM) T cell phenotypes
Spleen harvested from MMC sensitized large tumor-bearing (tumor volume≤2000mm³)
female FVBN202 mouse was crushed and processed to yield single cell suspensions
which were subjected to a 7-day expansion with alternating gamma chain cytokines.
The ex vivo expanded and freshly isolated T cells were stained with CD62L, CD44 and
CD8/CD4 antibodies. Gated CD8+ and CD4+ T cells were analyzed within 50,000
viable cells for the expression of CD44 and CD62L. The CD44+CD62L- (TE), CD44+
CD62Llow (TEM), CD44+CD62Lhigh (TCM) and CD44-CD62L+ (TN) phenotypes are
shown.
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Figure 6: Ex vivo expanded T cells with the alternating gamma chain cytokines
produce more IFN-γ than freshly isolated T cells upon in vitro stimulation with neu
positive MMC
The ex vivo expanded and freshly isolated T cells were cultured either alone or with
irradiated neu+ MMC (15000 rad) in the effector:target ratio of 10:1 for 24 hours and
supernatants were tested for IFN-γ secretion by using ELISA.
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To confirm the anti-tumor efficacy in vitro, T cells were co-cultured with viable MMC
target cells (E:T ratio of 10:1) for 48 hours followed by staining with antibodies
directed towards neu, Annexin V and PI. Control wells were seeded with MMC in the
absence of T cells. Gated neu positive MMC cells were analyzed for Annexin V and PI
to determine apoptosis of tumor cells by freshly isolated as well as the ex vivo expanded
T cells. Figure 7 shows that viability (Annexin V-/PI-) of MMC decreased from
92.26% in the absence of T cells to 68.57% and to 61.69% in the presence of freshly
isolated and the ex vivo expanded T cells, respectively.
To test the anti-tumor response potential in vivo, the ex vivo expanded T cells were used
for AIT in FVBN202 mice challenged with neu positive MMC. Prior to transfer of the
ex vivo expanded T cells, animals were treated with Cyclophosphamide (CYP) for
lymphodepletion. Control mouse did not receive AIT. Figure 8 shows the failure of T
cells expanded with the alternating gamma chain cytokines to induce tumor rejection.
Since the alternating common gamma chain cytokine formulation could not support the
expansion of T cells that could cause tumor regression in FVBN202 mice, we came up
with the sequential common gamma chain cytokine regimen for the ex vivo expansion
of T cells. We hypothesized that continuation of T cell culture with IL-2 following
initial culture with IL-7 + IL-15 could support the expansion of CD8+ TE cells that,
compared to naïve or central/memory T cells, may be refractory to MDSCs and result in
tumor rejection upon AIT even in the presence of endogenous MDSCs.
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Figure 7: Ex vivo expanded T cells with the alternating gamma chain cytokines
did not show an enhanced anti-tumor efficacy compared to the freshly isolated T
cells
The freshly isolated and ex vivo expanded T cells were cultured with neu positive MMC
in an effector:target ratio of 10:1, the control wells were seeded with MMC alone and
cultured for 48 hours. The cells were stained with antibodies against neu, AnnexinV and
PI. Gated neu+ population were analyzed for Annexin V and PI.
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Figure 8: AIT by using T cells expanded with the alternating gamma chain
cytokines fail to cause tumor regression in vivo
FVBN202 mice were inoculated with MMC (3 million per mouse) and then injected i.v.
with 70 million of the ex vivo expanded T cells. Prior to AIT, mice received CYP
treatment to cause lymphodepletion. Control mice received CYP treatment and MMC
challenge but no AIT. The tumor growth was presented as volume.

50

Figure8

51

Results
Experimental designs
In order to improve anti-tumor efficacy of AIT we made two modifications in our
protocol. First, we decided to collect T cells from FVBN202 donors early during tumor
development when tumor volume was 200-400 mm3 rather than late during tumor
burden when tumor volume reached 2000 mm3. Secondly, we changed the alternating
gamma chain cytokine formulation to a sequential cytokine formulation (IL-7+ IL-15
followed by IL-2). Since IL-2 can cause activation-induced cell death (AICD), T cells at
late stage of differentiation would die and those at early stage of differentiation would
survive. This could enrich for effector and effector/memory phenotypes that may last
longer in vivo.

Figure 9 shows the schematic representation of the experimental

procedures. Spleens were harvested from MMC-sensitized tumor-bearing female
FVBN202 mice, crushed and processed to obtain single cell suspension. Freshly
isolated splenocytes were used for functional assay, in vitro anti-tumor responses, and
phenotype analysis as well as the ex vivo expansion. Splenocytes were stimulated with
Bryostatin-1/Ionomycin (B/I) + IL-2 (80 U/106 cells/ml) for 16 hours followed by an
initial culture with IL-7+IL-15 (10-20 ng/106 cells/ml) for 24 hours then pulsed with IL2 (20U/106 cells/ml). One day after, cells were split and cultured with IL-2 (40U/106
cells/ml) for the next 3-4 days. The ex vivo expanded T cells were used for in vitro
assays and AIT by i.v. route (7 x 107 cells/mouse). The recipients of AIT received
cyclophosphamide (100mg/Kg) 24 hours prior to AIT and were subjected to MMC
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challenge a few hours before AIT. Twenty three days after, when animals had rejected
primary

tumors,

they

were

further

challenged

with

MMC

without

any

cyclophosphamide in order to determine memory responses. On days 50 and 61
following primary tumor challenge, animals were challenged with ANV and MMC,
respectively. While one group received ANV on the contralateral side and MMC on the
same side, another group was challenged with ANV on the contralateral side only.
Naïve mice challenged with the tumor served as control. Animals were then sacrificed
and their T cells were analyzed in vitro.
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Figure 9: Schematic representation of the experimental design
Spleens were harvested from MMC-sensitized tumor-bearing (either bearing small or
large tumors) female FVBN202 mice, crushed and processed to obtain single cell
suspension. Freshly isolated splenocytes were used for functional assay, in vitro antitumor responses, and phenotype analysis as well as ex vivo expansion with sequential
common gamma chain cytokine formulation for AIT. Twenty three days after AIT,
when animals had rejected MMC tumors, they were further challenged with MMC
without any cyclophosphamide in order to determine memory responses. On days 50
and 61 following primary tumor challenge, animals were challenged with ANV on the
contralateral side and/or with MMC, respectively. While one group received ANV on
the contralateral side and MMC on the same side, another group was challenged with
ANV on the contralateral side only. Naïve mice challenged with the tumor served as
control. 71- 80 days after the primary tumor challenge animals were sacrificed and their
splenic T cells were subjected to in vitro analyses.
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Sequential common gamma-chain cytokines expand T cells, preferentially CD4+ T
cells, from FVBN202 donor mice bearing small tumors
Spleens were harvested from FVBN202 donors 10-14 days after MMC challenge, when
tumor volume was between 150mm³-300mm³. These tumor-sensitized T cells were
nurtured and proliferated in the presence of sequential gamma chain cytokines and
exhibited high anti-tumor efficacy. We first determined the level of MDSCs in the
spleen of donor mice. Figure 10A shows that MDSCs accounted for 17.91% gated and
6.25% total splenocytes. Figure 10B shows two major subsets of MDSCs.
Ly6C+Ly6G- subsets accounted for 18.44% on gated CD11b+ and 0.68% of total
splenic cells while Ly6C+Ly6G+ subsets accounted for 69.51% gated CD11b+ and
2.1% of total splenic cells. Prior to, during and after the ex vivo expansion of
splenocytes, trypan blue exclusion was performed to determine the fold expansion.
Figure 11 shows the fold expansion of splenocytes that was comparable to that of the
alternating gamma chain cytokines (Figure 2). There was about 2.9 fold reduction after
B/I stimulation compared to day 0 baseline. On day three, five and six, number of cells
increased consistently, ultimately expanding up to 1.9 and 6.5 fold on day 6 compared
to day 0 and post-B/I activation. We then performed flow cytometry analysis of T cell
subsets to determine their relative proportions. All gated CD4+ or CD8+ cells were
found to be CD3+ which proves they were bona fide T cells (Figure 12, lower panel).
Both CD8+ and CD4+ T cells were expanded in the presence of the sequential gamma
chain cytokines (Figure 13). Rate of expansion was relatively lower than when the
alternative gamma chain cytokines was used (Figure 3). Unlike the alternating common
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gamma chain cytokines, the sequential cytokines preferentially expanded CD4+ T cells
(Figures 3 and 13) such that the proportion of CD4+ T cells was higher than CD8+ T
cells after the expansion.
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Figure10: FVBN202 donor mice bearing small tumors have a moderate level of
endogenous splenic MDSCs
Spleens harvested from MMC-sensitized tumor bearing (tumor volume=150-300mm³)
female FVBN202 mice were stained with antibodies against CD11b, Ly6G, and Gr1
(Ly6C). A total of 100,000 cells were analyzed by flow cytometry to examine the level
of endogenous MDSCs and its monocytic and granulocytic subpopulation. (A) percent
total and percent gated population of CD11b+Gr1+ (upper right quadrant) MDSCs. (B)
percent gated and percent total population of CD11b+Gr1+ subsets. The Ly6C+Ly6G(upper left quadrant) shows the suppressive monocytic subpopulation whereas the
Ly6C+Ly6G+ (upper right quadrant) depicts non-suppressive subpopulation. The bar
graphs with error bars show the average values from three different mice±SD.

58

Figure 10

59

Figure 11: Ex vivo expansion of splenocytes with sequential (IL-7/IL-15→IL-2)
gamma chain cytokines
Spleens harvested from MMC-sensitized tumor bearing (tumor volume=150-300mm³)
female FVBN202 mice (n=2) were crushed and processed to yield single cell
suspensions which were subjected to 6 day expansion with sequential common gamma
chain cytokines. T cells were incubated with 5nM Bryostatin-1 and 10nM Ionomycin
along with 80 U/ml of IL-2 in complete medium for 16 hours followed by expansion
with IL-7/IL-15 (10ng/ml), and then with IL-2 (40U/ml). Cell counts were performed
using trypan blue exclusion.
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Figure 12: The sequential common gamma chain cytokine formulation
preferentially expands CD3+ T cells
The ex vivo expanded T cells were stained with CD8, CD3 and CD4 antibodies and
100,000 viable cells from each sample were analyzed by flow cytometry to examine the
percentage of CD3+ cell among the expanded population. Gated CD8+ or CD4+ cells
were then analyzed for the expression of CD3.
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Figure 13: Expansion of splenocytes with the sequential common gamma chain

cytokines results in the expansion of CD8+ and CD4+ T cells
Splenocytes were stained with antibodies towards CD8 and CD4 prior to and after a 6day expansion. Percent total of gated CD8+ and CD4+ T cells were determined.
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The ex vivo expanded T cells show reduced viability
The success of adoptive immunotherapy depends on viability of the ex vivo expanded T
cells. First, in order to determine whether MMC stimulation may affect viability of T
cells, freshly isolated splenocytes were cultured in the presence or absence of MMC for
24 hours. As shown in Figure 14, Annexin V- viable T cells did not change
dramatically after the stimulation with MMC (p > 0.2). Viability of freshly isolated
CD8+ T cells was 61.67% of which CD8high T cells had higher viability than CD8low T
cells (Figure 14A; 72.05% vs. 14.13%, p =0.0000031). Because of a 24 hour culture of
the freshly isolated T cells there was a reduction in viability which made it impossible
to compare it with the viability of T cells after the ex vivo expansion. However, we
know that viability of the freshly isolated T cells is above 87% (Figure 4). Considering
that expansion of T cells with the sequential common gamma chain cytokines resulted
in a reduced viability of CD8+ and CD4+ T cells (Figure 14B) compared to T cells
expanded with the alternating common gamma chain cytokines (Figure 4).
Ex vivo expanded T cells with the sequential common gamma chain cytokines show
an increased tumor-specific IFN-γ production in vitro
In order to determine whether T cells expanded with the sequential common gamma
chain cytokines were enriched for tumor-reactive phenotypes, we performed in vitro
assays. Freshly isolated T cells or ex vivo expanded T cells were cultured either with (+)
or without irradiated MMC (-) for 24 hours and then analyzed for their activation.
Figure 15A shows negligible production of MMC-induced IFN-γ by freshly isolated T
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cells whereas the ex vivo expanded T cells produced significant amounts of IFN-γ upon
stimulation with MMC (p=0.002), as determined by IFN-γ ELISA. In order to
determine the cellular source of the IFN-γ production, flow cytometry analyses were
performed. Figure 15B shows a 5.3 fold higher proportion of CD8+ IFN-γ+ T cells
upon MMC stimulation (from 1.23% to 6.53%, p=0.04) whereas CD4+ T cells did not
show any significant increase in IFN-γ production (p=0.18). Increased IFN-γ production
were noticeable in both CD8high (p=0.042) and CD8low (p=0.037) T cells.
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Figure 14: Viability of freshly isolated and ex vivo expanded T cells
The lymphocytes were harvested from MMC-sensitized small tumor-bearing (tumor
size=150-300 mm³) female FVBN202 mice and subjected to 6 day expansion with the
sequential common gamma chain cytokines. Freshly harvested lymphocytes were
cultured alone or with irradiated MMC in the effector:target ratio of 10:1 for 24 hours
and stained with antibodies towards CD8, CD4 and AnnexinV. The ex vivo expanded T
cells were cultured alone and stained similarly. The upper left quadrants representing
CD8+AnnexinV-/CD4+AnnexinV- are considered to be viable. The middle panel
shows the gating pattern, how CD8 high and low population was separated.
Representative dot plots (A) as well as average of the means for two separate
experiments (B) are shown.
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Figure 14B

70

Figure 15: T cells expanded with the sequential common gamma chain cytokine
formulation can produce more IFN-γ than freshly isolated T cells upon in vitro
stimulation with MMC tumor cells
Freshly isolated and ex vivo expanded T cells were either cultured alone or with
irradiated MMC in an effector:target ratio of 10:1 for 24 hours and supernatants were
tested for IFN-γ secretion. (A) data from IFN-γ ELISA, representing IFN-γ secretion by
freshly isolated (left panel) and ex vivo expanded (right panel) T cells with and without
MMC stimulation. (B) represents dot plots from flow cytometric analyses of IFN-γ
staining for CD8+ and CD4+ T cells. A total of 100,000 cells of each sample was
analyzed. The bar graph with error bars represents the average of percent gated
population of IFN-γ+CD8+, IFN-γ+CD8high+, IFN-γ+CD8low+, IFN-γ+CD4+
populations from two different experiments.
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Ex vivo expanded T cells with the sequential common gamma chain cytokines show
an increased tumor-specific perforin (Prf) production as well as granzyme B (GrB)
and CD69 expression in vitro
Perforin (Prf) is a cytotoxic protein aids in delivering contents of granules into the
cytoplasm of target cells. These granules can cause apoptosis of the target cells. The
increased production of Prf by T lymphocytes can be considered as “marker” of
cytotoxic potential of T cells. Therefore, we looked at the ability of T cells to produce
Prf in tumor-specific fashion. Freshly isolated CD4+ T cells were found to have marked
increase in the number of cells producing perforin (Prf) upon MMC stimulation (0.63%
vs. 2.98%, p=0.02) whereas CD8+ T cells did not show any appreciable changes (1.49%
vs. 2.94, p=0.3) (Figure 16). The ex vivo expanded T cells did not show any marked
increase in Prf production upon MMC stimulation (Figure 17). However, compared to
freshly isolated T cells, only marginal increase in Prf production was detected in the ex
vivo expanded CD8+ T cells (Figures 16 and 17; 1.49% vs. 2.74%, p=0.17).
Granzyme-B is a serine protease which activates apoptosis once within the target cells.
Both CD4+ and CD8+ T cells, either freshly isolated (Figure 18) or ex vivo expanded
(Figure 19), showed high expression of GrB (> 90%) and it did not increase upon
MMC stimulation in vitro.
The early activation marker, CD69, showed a 2.82 fold increase in freshly isolated
CD8+ T cells (10.23% vs. 28.86%, p=0.002) and a 1.99 fold increase on CD4+ T cells
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(19.13% vs. 38.19%, p=0.001) when stimulated with MMC (Figure 20). Importantly,
the ex vivo expanded CD8+ T cells showed significantly higher expression of CD69
compared to freshly isolated ones (Figures 20 and 21; 10.23% vs. 81.06%, p=0.04)
whereas no increases were detected on CD4+ T cells following the ex vivo expansion
(Figures 20 and 21; 19.13% vs. 14.85%, p=0.16). These ex vivo expanded CD8+ T
cells and CD4+ T cells showed no significant increase in CD69 expression upon MMC
stimulation in vitro (Figure 21, CD8+ T cells: 81.06 vs. 84.41%, CD4+ T cells: 14.85%
vs. 18.87%, p=0.2).
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Figure 16: Freshly isolated CD4+ T cells show increased production of Prf upon in
vitro stimulation with MMC
Splenocytes of FVBN202 donors bearing small tumors were stained with CD8, CD4
and Prf antibodies before and after a 24-hour stimulation with irradiated MMC. A total
of 100,000 cells per sample were analyzed to detect the production of Prf. Gated CD8+
and CD4+ T cells were analyzed for the detection of Prf. The bar graphs with error bars
represent the average values from three different animals.
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Figure 17: T cells expanded with the sequential common gamma chain cytokine
formulation show higher basal level of endogenous perforin (Prf) than freshly
isolated T cells but fail to increase Prf upon MMC stimulation
Splenocytes harvested from MMC-sensitized small tumor-bearing female FVBN202
mice were subjected to 6 day expansion with the sequential common gamma chain
cytokines and were stained with CD8, CD4 and Prf antibodies before and after
stimulation with MMC. A total of 100,000 cells per sample were analyzed by flow
cytometry. Gated CD8+ and CD4+ cells were analyzed for the expression of Prf. The
bar graph with error bars represents the average values of two different experiments.
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Figure 18: Freshly isolated T cells show high level of granzyme-B (GrB)
production
A total of 100,000 cells per sample were analyzed to detect the production of GrB on
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with
error bars represent the average values from three different animals examined separately
in a single experiment.
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Figure 19: T cells expanded with the sequential common gamma chain cytokine
formulation show high level of granzyme B (GrB)
A total of 100,000 cells per sample were analyzed to detect the production of GrB on
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with
error bars represent the average values from three different animals examined separately
in a single experiment.
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Figure 20: The CD8+ and CD4+ T lymphocytes harvested freshly from MMCsensitized small tumor-bearing (tumor volume=150-300mm³) female FVBN202
mice show significant expression of CD69 on MMC stimulation
A total of 100,000 cells per sample were analyzed to detect the expression of CD69 on
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with
error bars represent the average values from three different animals examined separately
in a single experiment.
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Figure 21: The ex vivo expanded T cells with the sequential common gamma chain
cytokines show an increased basal level of CD69 expression even in the absence of
MMC stimulation in vitro
A total of 100,000 cells per sample were analyzed to detect the expression of CD69 on
gated CD8+ and CD4+ cells before and after MMC stimulation. The bar graphs with
error bars represent the average values from three different animals examined separately
in a single experiment.
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T cells expanded with the sequential common gamma chain cytokines are highly
effective against the tumor and are refractory to MDSCs in vivo
In order to determine whether the ex vivo-expanded tumor-reactive T cells may also
protect FVBN202 mice against tumor challenge even in the presence of endogenous
MDSCs, AIT was performed. FVBN202 mice were challenged with MMC 24 hours
after cyclophosphamide injection. Animals were split into two groups; the control group
remained untreated whereas the test group was subjected to AIT in the absence of
MDSC depletion in vivo. Figure 22 shows complete rejection of the tumor following
AIT. The control mice (without AIT) developed tumors, as expected.
In order to determine the phenotype distribution of T cells, flow cytometry analyses
were performed. Figure 23 shows the phenotypic distribution of CD8+ and CD4+ T
cells in the freshly isolated splenocytes. TCM and TN phenotypes were the most abundant
cells for both CD8+ and CD4+ T cells. CD8+ T cells consisted of 5.62% effector (TE),
9.91% of effector memory (TEM), 57.23% central memory (TCM) and 26.28% of naïve
(TN) phenotypes. The CD4+ T cells were of 7.97% effector, 7.77% effectors memory,
59.98% central memory and 22.61% of naïve phenotypes. Phenotypic distribution of the
ex vivo expanded T cells is shown in Figure 24. The ex vivo expanded CD8+ T cells
showed marked increases in TE and TEM phenotypes whereas CD4+ T cells showed an
increased TE and TCM phenotypes compared to the freshly isolated T cells (Figures 23
and 24). The ex vivo expanded CD8+ T cells consisted of 43.90% effector, 16.40%
effectors memory, 36.43% central memory, and 1.75% naïve phenotypes. The CD4+ T
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cells were of 26.33% effector, 9.58% effector memory, 61.27% central memory, and
1.95% naïve phenotypes.
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Figure 22: T cells expanded with the sequential common gamma chain cytokines
are highly effective against the tumor and are refractory to MDSCs in vivo
The ex vivo expanded T cells were used for AIT in FVBN202 mice (n=3) challenged
with 3 million MMC. Mice were treated with CYP for lymphodepletion. The control
mice (n=2) received CYP treatment and MMC challenge but no AIT. The figure shows
the tumor growth pattern of the control (upper panel) and the recipient of AIT (lower
panel).
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Figure 23: Phenotypic distribution of freshly isolated T cells harvested from
MMC-sensitized small tumor-bearing FVBN202 mice
The freshly isolated T cells were stained with CD44, CD62L and CD8/CD4 antibodies
and fluorescence of 100,000 viable cells were analyzed by flow cytometry. The lowest
panel is a representative dot plot with the quadrants marked for the distribution of
various phenotypic subsets of T cells. The upper left panel represents the auto
fluorescence of the sample and the fluorescence for single colored antibodies. The
upper middle panel shows the phenotypic distribution of the CD8+ and CD4+ T cells.
The bar graphs with error bars (upper right panel) represent the average of 3 different
animals examined in a single experiment.
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Compared to freshly isolated CD8+ T cells, the ex vivo expanded cells showed a
marked shift toward effector cells (Figures 23 and 24; 5.62% vs. 43.9%, p=0.02) and
effector/memory cells (9.91% vs.16.4%, p=0.004) whereas central/memory cells
decreased from 57.23% to 36.4% (p=0.006). A marked decrease was also observed in
naïve CD8+ T cells (26.28% vs. 1.7%, p=0.0001). The MFI for CD44 expression in
CD8+ T cells was 85.2 which were over 14 fold higher than that expressed in T cells
expanded with the alternating gamma chain cytokines (Figure 5). Compared to freshly
isolated CD4+ T cells, the ex vivo expanded CD4+ T cells showed an increase in
effector phenotypes (7.97% vs. 26.33%, p=0.1) while no changes were observed in
effector/memory (7.77% vs. 9.58%, p=0.28) and central/memory (59.98% vs. 61.27%,
p=0.42) phenotypes. Naïve CD8+ T cells showed a marked decrease following the ex
vivo expansion (22.61% vs. 1.95%, p=0.001). The MFI for CD44 expression in CD4+ T
cells was 51.5 which was 8-10 fold higher than that expressed in T cells expanded with
the alternating gamma chain cytokines (Figure 5).
Sequential common gamma chain cytokines support the proliferation and
differentiation of T cells that are highly effective against the tumor and are
refractory to MDSCs in vitro
Since the ex vivo-expanded T cells with the sequential common gamma chain cytokines
showed an increased tumor-reactivity in vitro evidenced by the production of IFN-γ and
CD69 expression as well as an anti-tumor efficacy in vivo, we sought
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to determine whether the expanded T cells would show an enhanced cytotoxicity
against the tumor cells in vitro. Freshly isolated or ex vivo expanded T cells were cocultured with MMC target cells (E:T ratio of 10:1) for 48 hours followed by staining
with antibodies directed towards neu, Annexin V and PI. Control wells were seeded
with MMC in the absence of T cells. Gated neu positive cells were then analyzed to
detect apoptosis (AnnexinV+ and PI+ cells). Figure 25 shows the result of cytotoxicity
assays in vitro. The control MMC cells in the absence of T cells showed 87.50%
viability (AnnexinV-/PI-). Viability of MMC dropped to 50.79% in the presence of
freshly isolated T cells. When co-cultured with the ex vivo expanded T cells the
viability of MMC dropped from 68.8% to 17.6% (p=0.000027). By normalizing the
viability of control MMC to 100%, the ex vivo expanded T cells were found to be more
efficient in inducing apoptosis of tumor cells than freshly isolated T cells.
Since AIT with the ex vivo expanded T cells using sequential gamma chain cytokines
but not alternating gamma chain cytokines induced tumor rejection, even in the absence
of MDSC depletion in vivo, we hypothesized that the sequential gamma chain cytokine
regimen supported proliferation and differentiation of T cells that are refractory to the
inhibitory effects of MDSCs. In order to test this, T cells were co-cultured with MMC
in the presence or absence of MDSCs in vitro. Figure 26A shows that the ex vivo
expanded T cells produced a significantly more IFN-γ in the presence of irradiated
MMC when compared with T cells alone (T vs. T+MMC p=0.035). In addition,
presence of MDSCs at 2:1 ratio (T: MDSCs) did not inhibit MMC-specific IFN-γ
production, with a marginal increase in the level of IFN-γ (p= 0.09). No significant
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secretion of IFN-γ was detected in MMC, MDSCs or T cells alone. To determine
cellular source of IFN-γ production we performed flow cytometry analyses. The gating
patterns used for the analyses are shown in Figure 26B; the lymphocyte region was first
gated and CD8+ T cells and CD4+ T cells were re-gated out in order to determine IFN-γ
production by the T cell subsets. Figure 26C shows that the ex vivo expanded CD8+ T
cells produced IFN-γ when stimulated with MMC in the absence or presence of MDSCs
(0.75% vs. 11.67% or vs. 30.04%). The CD4+ T cells also showed increased IFN-γ
production upon MMC stimulation in the absence or presence of MDSCs (0.29%
vs.3.24% or vs.11.23%). There were significant increases in IFN-γ production by CD8+
(p=0.04), CD8high (p=0.04) and CD8low (p=0.037) T cells upon MMC stimulation
whereas CD4+ T cells showed a negligible increase (p=0.18) in IFN-γ production.
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Figure 24: Phenotypic distribution of the T cells harvested from MMC-sensitized
small tumor-bearing FVBN202 mice and expanded with the sequential common
gamma chain cytokines
T cells were stained with CD44, CD62L and CD8/CD4 antibodies and fluorescence of
100,000 viable cells were analyzed by flow cytometry. The far left panel represents the
auto fluorescence of the sample and the fluorescence for single colored antibodies. The
middle panel shows the phenotypic distribution of the CD8+ and CD4+ T cells. The bar
graphs with error bars (right panel) represent the average values of two different
experiments.
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Figure 25: T cells expanded with the sequential gamma chain cytokines show
more anti-tumor efficacy than freshly isolated lymphocytes
The cells were stained with antibodies against neu, AnnexinV and PI. The neu+ cells
were gated and viability was determined. The lower left panel represents the viable
population (AnnexinV- PI-). The figure shows the viability of MMC control and MMC
cultured with freshly isolated lymphocytes(upper panel) and MMC control and MMC
cultured with ex vivo expanded T cells (lower panel). In the bar graph the viability of
control MMC has been normalized to 100%. The bar graph (above) represents the
average of 3 animals and the bar graph (below) shows the average values from 2
different experiments.
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Figure 26: T cells expanded with sequential common gamma chain cytokines
produce tumor-specific IFN-γ even in the presence of MDSCs
The T cells expanded ex vivo with sequential common gamma chain cytokines were
cultured alone, with irradiated MMC and together with irradiated MMC and MDSC in
the Effector:Target:MDSC ratio of 10:1:5 for 24 hours and the supernatants were tested
for the level of secreted IFN-γ. (A) represents data of IFN-γ ELISA and shows that T
cells can produce more IFN-γ on stimulation with MMC even in presence of MDSC.
The error bars show the average values from two different experiments. (B) represents
the gating pattern followed to gate out the CD8+ and CD4+ T cells during flow
cytometry analyses, in order to confirm that the potential source of IFN-γ is the T
lymphocytes but not the MDSC. (C) ex vivo expanded T cells were stained with the
CD8, CD4 and IFN-γ antibodies and flow cytometry analyses were done. The upper
panel shows the amount of IFN-γ produced by T cells alone and by T cells on MMC
stimulation. The middle panel represents the histogram showing that the contribution of
MMC in IFN-γ production was negligible, and the lower panel shows the level of IFN-γ
secreted by cells when cocultured with MDSCs. The bar graph with error bars
represents the average values from two different experiments.
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Figure 27: T cells expanded with the sequential common gamma chain cytokines
are refractory to the inhibitory effects of MDSCs and can produce perforin (Prf)
upon MMC stimulation even in presence of MDSCs
The T cells expanded ex vivo with sequential common gamma chain cytokines were
cultured alone, with irradiated MMC and together with irradiated MMC and MDSC in
the Effector:Target:MDSC ratio of 10:1:5 for 24 hours and the supernatants were tested
for the level of Prf. The ex vivo expanded T cells were stained with CD8, CD4 and Prf
antibodies and flow cytometry analyses were done. The upper panel shows the amount
of Prf produced by T cells alone and by T cells on MMC stimulation. The middle panel
represents the histogram showing the contribution of MMC in Prf production was
negligible, and the lower panel shows the level of IFN-γ secreted by cells when
cocultured with MDSCs. The bar graph with error bars represents the average values
from two different experiments.
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Presence of MDSCs slightly increased IFN-γ production by CD8+ T cells upon MMC
stimulation, though it was not found to be significant (p=0.09). A similar trend as to the
effects of MDSCs on T cell responses was detected for perforin production by the ex
vivo expanded T cells (Figure 27). Initially 8.62% of CD8+T cells were found to be
positive for perforin, the percentage increased slightly to 10.12% and further to 32.34%
when co-cultured with MMC alone and MMC+MDSC, respectively. The percentage of
CD4+ Prf+ T cells increased from 2.37% to 7.24% with MMC alone and further to
11.07% with MMC + MDSCs. Although there was increased perforin production by T
cells stimulated with MMC in presence or absence of MDSCs, the statistical analyses of
the repeat experiments revealed no significant differences (for CD8+ cells; T vs.
T+MMC p=0.28; T vs. T+MMC+MDSC p= 0.14).
Figures 28 and 29 show that addition of MDSCs did not alter the Granzyme-B
production nor did alter the expression of CD69.
Finally, in vitro cytotoxicity assays revealed that the ex vivo expanded T cells can kill
MMC even in the presence of MDSCs (Figure 30). Neu positive MMC target cells
were co-cultured with the ex vivo expanded T cells in the presence or absence of
MDSCs (E:T:MDSC ratios of 10:1:5) for 48 hours followed by staining with antibodies
directed towards neu, Annexin V and PI. Control wells were seeded with MMC in the
absence of T cells. Gated neu positive cells showed apoptosis in the presence of T cells
regardless of the presence or absence of MDSCs. Viability of MMC dropped from
74.87% to 3.66% (p= 0.004) when co-cultured with T cells and was further reduced to
107

1.22% (p =0.003) in the presence of MDSCs. There were no significant differences in
the apoptosis of MMC induced by T cells in the presence or absence of MDSCs (p=
0.3).
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Figure 28: T cells expanded with the sequential common gamma chain cytokines
are refractory to the inhibitory effects of MDSCs and can maintain unaltered
Granzyme-B (GrB) upon MMC stimulation and in the presence of MDSC
The ex vivo expanded T cells were stained with the CD8, CD4 and GrB antibodies and
flow cytometry analyses were done. The upper panel shows the amount of GrB
produced by T cells alone and by T cells upon MMC stimulation and the lower panel
shows the level of GrB secreted by cells when co-cultured with MDSCs. There is no
increase in GrB production upon MMC stimulation as the endogenous level has reached
saturation.
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Figure 29: T cells expanded with the sequential common gamma chain cytokines
are refractory to the inhibitory effects of MDSCs and can maintain unaltered
expression of CD69 upon MMC stimulation even in presence of MDSCs
The ex vivo expanded T cells were stained with the CD8, CD4 and CD69 antibodies and
flow cytometry analyses were done. The upper panel shows the amount of CD69
expressed by T cells alone and by T cells upon MMC stimulation and the lower panel
shows the level of CD69 expression by cells when co-cultured with MDSCs. There is
no marked increase in CD69 expression as the endogenous level has reached saturation.
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Figure 30: T cells expanded with the sequential common gamma chain cytokines
show an enhanced cytotoxicity against MMC compared to freshly isolated T cells
even in the presence of MDSCs
The freshly isolated and the ex vivo expanded T cells were cultured with MMC or with
MMC and MDSC in the Effector: Target:MDSC ratio of 10:1:5. The control wells were
seeded with MMC alone and cultured for 48 hours. The cells were stained with neu,
AnnexinV and PI antibodies. The neu+ cells were gated and viability was determined.
In the bar graph the viability of control MMC has been normalized to 100%. The dot
plots represent the viability of the control MMC and MMC co-cultured with T cells and
MDSCs. The bar graph shows the average values from 2 different experiments.

113

Figure 30

114

Sequential common gamma chain cytokines expand tumor-reactive T cells derived
from the FVBN202 donors bearing large tumors
Since donors of T cells that were expanded with the alternating gamma chain cytokines
were harboring large tumors whereas those expanded with the sequential gamma chain
cytokines had small tumors, we sought to determine whether the source of T cells
during early versus late tumorigenesis may be responsible for the differential effects
that we observed. In order to test this possibility, we collected T cells from FVBN202
donors carrying large tumors (>1000 mm3) and expanded them with sequential gamma
chain cytokines followed by in vitro and in vivo analyses. Figure 31 shows the level of
MDSCs in the spleen of donors, accounting for 73.4% of the granulocyte gated and
9.3% of the total splenocytes. Spleens from two donors were harvested 21 days after
MMC challenge, pooled together, and subjected to a 6-day expansion with the
sequential gamma chain cytokines. Figure 32 shows a drop from 150 million cells to
77.7 million cells after the B/I activation followed by the expansion to 805.98 million
cells on day six. There was 5.37 and 10.36 fold increase of T lymphocytes compared to
day 0 and post B/I activation respectively. T cells expanded with the sequential
common gamma chain cytokines showed better expansion potential than with those
expanded with the alternating gamma chain cytokine regimen. Figure 33 shows that the
ex vivo expanded CD8+ T cells increased from 4.06% to 25.88% (6.37 fold) and CD4+
T cells increased from 12.15% to 46.78% (3.85 fold). The expanded T cells were used
for further in vitro experiments to assess the anti-tumor responses. Figure 34A shows a
marked increase in IFN-γ production by the ex vivo expanded T cells stimulated with
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MMC (CD8+ T cells: 5% vs. 30%; CD4+ T cells: 0.1% vs. 1%). A similar trend was
detected when T cells were analyzed for the expression of perforin (Figure 34B).
CD8+Prf+ T cells were increased from 58% to 84% and CD4+Prf+ T cells were
increased from 7% to 16.4%, when stimulated with MMC in vitro. Compared to the
expanded T cells derived from donors bearing small tumors (Figure 17), those from
donors with large tumors (Figure 34B) showed increase in CD8+Prf+ T cells in the
absence (2.74% vs. 58%) or presence of MMC (6.15% vs. 84%). Similar trends were
detected for CD4+Prf+ T cells in the absence (1.1% vs. 7%) or presence (0.56% vs.
16.4%) of MMC. Similar to the T cells derived from mice with small tumors (Figure
28); T cells derived from mice with large tumors (Figure 34C) expressed high levels of
GrB before or after MMC stimulation. Similar trends were observed for the expression
of CD69 (Figure 34D). CD8+CD69+ T cells were increased from 63% to 79%, when
stimulated with irradiated MMC. CD4+CD69+ T cells were also increased from 6.4%
to 10%, when stimulated with MMC. There were no significant differences in the
expression of CD69 comparing the T cells derived from mice with small tumors
(Figure 29) and those from mice with large tumors (Figure 34D).
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Figure 31: The level of endogenous MDSCs is very high in the FVBN202 donors
bearing large tumors
The splenocytes were harvested from the MMC tumor-bearing female FVBN202 mice
and were stained with CD11b and Gr1 antibodies to determine the level of endogenous
splenic MDSCs. The figure represents a very high CD11b+Gr1+ MDSC level (upper
right quadrant). Both the percent total and percent gated values are being shown in the
data.
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Figure 32: Ex vivo expansion of splenocytes of FVBN202 donors bearing large
tumors using the sequential (IL-7/IL-15→IL-2) gamma chain cytokines
Spleens harvested from MMC-tumor bearing (tumor size> 1000mm³) female FVBN202
mice were crushed and processed to yield single cell suspension which were subjected
to a 6-day expansion with the sequential common gamma chain cytokines. Cell counts
were determined by trypan blue exclusion.
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Figure 33: Ex vivo expansion of T cells of FVBN202 donors bearing large tumors
using the sequential (IL-7/IL-15→IL-2) gamma chain cytokines
Flow cytometry analyses of the percent total population of CD8+ and CD4+ T cells
before and after the expansion with the sequential common gamma chain cytokine
formulation.
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Figure 34: Production of IFN-γ, perforin and granzyme B as well as the expression
of CD69 by the ex vivo expanded T cells harvested from FVBN202 donors bearing
large tumors
The ex vivo expanded T cells were cultured alone or with irradiated MMC in the ratio of
10:1 for 24 hours and stained with CD8, CD4 and specific antibodies against various
surface and internal molecules which are considered to be the marker of anti-tumor
responses. Fluorescence for 100,000 viable cells was analyzed by flow cytometry. (A)
represents MMC-induced IFN-γ production by CD8+ and CD4+ T cells. (B) perforin
production by both CD8+ and CD4+ T cells. (C) Granzyme-B production by both
CD8+ and CD4+ T cells. (D) expression of CD69 by both CD8+ and CD4+ T cells
upon MMC stimulation.
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We also tried to compare the phenotypic distribution of freshly isolated and the ex vivo
expanded T cells. It is clear from the data that the ex vivo expanded CD8+ T cells were
of effector and effector/memory while CD4+ T cells were of effector and
central/memory phenotypes (Figure 35) similar to what was detected when T cells were
isolated from FVBN202 donors bearing small tumors and expanded with the sequential
gamma chain cytokines (Figure 24). The ex vivo expanded T cells showed 56%
effector, 16% effectors/memory, 22% central/memory, and 4% naïve phenotypes
(Figure 35). The MFI for CD44 was 30.9 which was over 6 fold higher than that
expressed in CD8+ T cells expanded with the alternating common gamma chain
cytokines (Figure 5). The CD4+ T cells consisted of 26% effector, 10%
effector/memory, 60% central/memory, and 3.5% naïve phenotypes. The MFI for CD44
was 33.1 which was 4-5 fold higher than that expressed in CD4+ T cells expanded with
the alternating common gamma chain cytokines (Figure 5). Stimulation of these T cells
with irradiated MMC, in vitro, did not change the proportion of T cell phenotypes
(Figure 35). These phenotypic distributions remained the same after MMC stimulation.
Ex vivo expansion of T cells with the sequential common gamma chain cytokines
render them refractory to MDSCs in vivo and generate long term memory
responses against mammary tumors
Since CD8+ T cells harvested from donors with large or small tumors showed
predominant effector and effector/memory phenotypes upon expansion with the
sequential gamma chain cytokines, we hypothesized that presence of effector/memory T
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cells might protect the mice against recall tumor challenge and might also provide
protection against relapsed tumors not expressing neu (ANV). To test our hypotheses,
FVBN202 recipients were inoculated with 5 million MMC for the second time on day
23 after the first inoculation without receiving cyclophosphamide or AIT. Control naïve
mice were inoculated with an equal number of MMC cells. Figure 36A shows that all
animals (n=3) rejected the recall tumor challenge within 14 days. Control mice
developed tumors, as expected. To determine whether memory T cell responses might
also protect the mice against neu negative relapsed ANV tumor cells, animals were split
into two groups. Group 1 was inoculated with 4 million ANV on the contralateral side,
13 days after rejecting the recall MMC, and with 5 million MMC (3rd challenge) 11
days after ANV challenge. Group 2 was only challenged with ANV on the contralateral
side. The control group was inoculated with an equal number of ANV cells only.
Figure 36B shows complete rejection of MMC and significant inhibition of ANV
compared to the control group. Group 2 also showed inhibition of ANV compared ANV
control mouse, though to a lesser degree compared to those inoculated with MMC,
simultaneously. In order to determine phenotypic distribution of T cells in these
recipient mice as well as the anti-tumor efficacy against MMC and ANV in vitro,
animals were sacrificed and their splenocytes were analyzed. Figure 37 represents the
phenotypic distribution of the T lymphocytes derived from the spleen of the animal
which received AIT and were challenged with MMC (2nd inoculation) and ANV. When
sacrificed the ANV tumor was about 600mm³. The data show predominant effector
phenotypes for both CD8+ and CD4+ T cells.
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In order to confirm reactivity of the T cells with both MMC and ANV, animals that
were challenged with MMC and ANV (group 1) were sacrificed when the ANV tumor
was about 74 mm³. Figure 38A shows the level of CD11B+Gr1+ MDSCs in the spleen
of the recipient mouse, accounting for 4.24% of the gated granulocyte region and 1.12%
of the total population. Gated CD11B+ population showed 5.67% Ly6G+Ly6C- and
17.93% of Ly6G-Ly6C+ as well as 12.87% of Ly6G+Ly6C+ population. As shown in
Figure 38B T cells showed an increased cytotoxicity against MMC (viability of MMC
reduced from 72.91% in the absence of T cells to 62.01% in the presence of T cells). T
cells also showed an increased cytotoxicity against CFSE-labeled ANV (Figure 38C;
from 84.19% in the absence of T cells to 51.88% in the presence of T cells).
Protein ELISA was conducted on the serum collected from the animals which received
tumor challenge followed by AIT and successfully rejected the tumor and showed
memory responses. 5 and 50 fold dilution series of the serum was prepared for the
ELISA; no antibody mediated response towards the tumor antigen was detected in these
animals (data not shown).
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Figure 35: Phenotypic distribution of the ex vivo expanded T cells harvested from
FVBN202 donors bearing large tumors and expanded with the sequential common
gamma chain cytokines
The ex vivo expanded T cells were stained with CD44, CD62L and CD8/CD4
antibodies and fluorescence of 100,000 viable cells was analyzed by flow cytometry.
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Figure 36: Ex vivo expansion of T cells with the sequential common gamma chain
cytokines generate long term memory responses against mammary tumors
The animals represented in Figure 22, when successfully rejected the primary tumor
after receiving AIT with the ex vivo expanded T cells were further re-challenged with 5
million of MMC (A). This time no CYP treatment or AIT was given to the animals. On
day 50 they received 4 million of ANV on the contralateral side and lastly on day 61,
one of them received a 3rd MMC re-challenge on the contralateral side of the previous
inoculation (B).
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Figure 37: Phenotypic distribution of T cells derived from the AIT recipients
The animal which received the second MMC challenge and ANV challenge was
sacrificed when the ANV tumor reached 600 mm³ volume and splenocytes were
harvested. The freshly isolated splenocytes were stained with CD44, CD62L and
CD8/CD4 antibodies. The phenotypic distribution was analyzed by flow cytometry. It
showed marked resemblance with the phenotypic distribution of the freshly isolated
donor’s lymphocytes.
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Figure 38: Presence of MDSCs in the spleen of the AIT recipients and anti-tumor
efficacy of their T cells against MMC and ANV
The recipient of AIT which received the ANV and the third MMC challenge was
sacrificed when the ANV tumor reached 76mm³ and the MMC tumor was about to
disappear (10mm³), the splenocytes were stained for detection of endogenous MDSCs
(A) and to test their cytotoxic potential against MMC (B) or ANV (C).
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CHAPTER 4 Discussions

Adoptive immunotherapy (AIT) includes isolation of lymphocytes from cancer patients,
expansion of tumor-reactive T cells ex vivo and infusion of these tumor-reactive T cells
back into the patient (45). Current protocols for AIT of cancers utilize the ex vivo
expansion of tumor-reactive T cells in the presence of T cell growth factors such as IL-2
or other pharmacological agents to generate a large number of such immune effector
cells (66). Recently, common gamma chain cytokines including IL-7, IL-15, and IL-21
have been used for the expansion of T cells (66-68). Previous pre-clinical reports have
suggested that the antigen-sensitized CD8+ T cells exhibit different trafficking and
phenotypic distribution as well as functional attributes when exposed to various
common receptor gamma chain cytokines. In the present study, we conducted
comparative analyses of two different cytokine regimens used in our laboratory for the
expansion of tumor-reactive T cells for AIT of breast carcinoma. We have recently used
the alternating (IL-7/IL-15→IL-2→IL-7/IL-15) and sequential (IL-7/IL-15→IL-2)
common gamma chain cytokine formulations for the ex vivo expansion of the
autologous T cells derived from the FVBN202 transgenic mouse model of Her-2/neu
positive breast carcinoma. In addition to determining the MDSC sensitivity of T cells
expanded with these two different cytokine regimens, we also determined whether the
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state of tumor burden during early or late tumorigenesis may affect the anti-tumor
efficacy of donor T cells after reintroduction into the tumor bearing animals.
Alternating and sequential common gamma chain cytokines expand tumorreactive T cells ex vivo
We have previously reported that B/I activation of the neu-specific high affinity T cells
derived from wild type FVB mice, and expansion in the presence of the alternating
common gamma chain cytokines enhanced anti-tumor efficacy of the T cells in vitro.
However, AIT using these T cells protected FVBN202 mice against challenge with the
neu positive MMC, only when combined with the depletion of MDSCs in vivo (37). In
the present studies we used FVBN202 transgenic mice as donors of low affinity T cells
against neu positive MMC. We found that the alternating and sequential common
gamma chain regimens ex vivo expanded tumor-reactive T cells, as evidenced by an
enhanced tumor-induced IFN-γ production as well as cytotoxicity against MMC in
vitro. These data argue against the notion that tumor-bearing FVBN202 animals are
tolerant to their tumor antigens because they harbored pre-existing tumor-specific T
cells that were expanded ex vivo. A recent report on pre-existing Her-2/neu-specific
immune responses in breast cancer patients (69) is consistent with our observation and
both argue against the existence of immunological tolerance in cancer patients.
T cells expanded with the sequential common gamma chain cytokines showed
comparable expansion and enhanced in vitro cytotoxicity but had a lower ratio of
CD8+ to CD4+ T cells, lower production of the tumor-induced IFN-γ and a higher
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proportion of apoptotic T cells compared to those expanded with the alternating
common gamma chain cytokines regimen
The alternating and sequential gamma chain cytokine formulations were equally
effective in fold expansion of T cells, regardless of the status of tumor burden of the
donors. However, these two regimens had differential effects on the expansion of CD4+
and CD8+T cells. While the alternating formulation results comparable yield of CD8+
and CD4+ T cells, the sequential formulation preferentially expands CD4+ T cells. The
expansion pattern revealed that the alternating gamma chain cytokine formulation
supported 9.2 fold and 3.4 fold expansion of the CD8+ and CD4+ T cells such that at
the end of the expansion the proportion of both subsets were similar. With sequential
cytokine regimen abundance of CD4+ T cells were maintained, regardless of the status
of tumor burden in the donors. However, fold expansion of CD8+ and CD4+ T cells
with the sequential gamma chain cytokines was lower when donors had small tumor
burdens.
Despite the lower ratio of CD8+ T cells over CD4+ T cells and greater numbers of
apoptotic T cells following the expansion with sequential gamma chain cytokines, these
T cells showed greater cytotoxic effects on MMC tumor cells in vitro. This greater
cytotoxicity was associated with lower titer of tumor-induced IFN-γ production by these
T cells compared to those expanded with the alternating gamma chain cytokines (3500
pg/ml vs. 30,000 pg/ml). Flow cytometry analysis revealed that tumor-induced IFN-γ
production was evident in CD8+ T cells but not in CD4+ T cells. These data suggest the
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perforin/granzyme B production by the tumor-reactive T cells. While freshly isolated
CD8+ and CD4+ T cells from FVBN202 mice showed minimal perforin production
(less than 3%) upon stimulation with MMC in vitro, majority of the ex vivo-expanded T
cells produced perforin in response to MMC stimulation (6-84% of CD8+ T cells and
0.56%-16% of CD4+ T cells). T cells isolated from animals with small tumor burdens
and expanded with the sequential gamma chain cytokines also showed a higher
percentage of CD8+Prf+ T cells compared to freshly isolated T cells (2-6% vs. 1.5%),
though less than T cells derived from the donors with large tumor burden. All T cells
showed high levels of granzyme B production regardless of cytokine formulation or
tumor burden in the donors. We have previously reported that high affinity T cells can
reject neu positive MMC tumor cells that lack expression of the receptor for IFN-γ,
suggesting the existence of IFN-γ-independent mechanisms of tumor rejection by T
cells (65). Significant in vitro tumoricidial activity of T cells expanded with sequential
gamma chain cytokines was evident regardless of the status of tumor burden in the T
cell donors. Others also reported that the presence of tumor-specific IFN-γ has been
producing T cells was not correlated with objective clinical responses in patients with
melanoma (70). Importantly, IFN-γ found to render some tumors, including uveal
melanoma cells, resistant to granule-mediated lysis by cytotoxic lymphocytes (71). It is
evident from these studies that sequential common gamma chain cytokine formulation
supports expansion of tumor reactive T cells that can preferentially induce IFN-γindependent mechanism of tumor regression.
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Sequential common gamma chain cytokine regimen was more efficient than the
alternating common gamma chain cytokine formulation for the expansion of
effector and effector/memory CD8+ T cells as well as effector and central/memory
CD4+ T cells
For effective and successful AIT, T cells should possess the effector function and
homing abilities to lymph nodes to induce tumor regression and protection from future
recurrence (50). The major cytotoxic function of the CD8+ T cells demands direct
cellular contact with the target cells. To induce tumor specific cell death, the effector
CD8+ T cells should reach the tumor site from blood. This potential extravasation
capacity depends on their ability to adhere to endothelial cells while withstanding
hydrodynamic shear stresses exerted by flowing blood. The tethering and rolling
mechanism is governed by the selectin family (51). According to Klebanoff et al, in the
presence of IL-15, CD8+ T cells differentiated to the central/memory phenotype while
IL-2 preferentially supported effector and effector/memory CD8+ T cells (72). As
expected, the alternating gamma chain cytokine formulation maintained CD8+ and
CD4+ central memory phenotypes after a 6-day expansion (CD8+ T cells: from 51.4%
to 53.3% and CD4+T cells: from 58% to 40%) with small increases in effector
phenotypes (CD8+ T cells: 2.2. fold increase and CD4+T cells: 1.3 fold increase).
Overall, central memory and effector phenotypes were abundant after the expansion
with alternating gamma chain cytokines. This regimen caused a marked reduction of
naïve T cell population for the CD8+ subsets. On the other hand, the sequential
common gamma chain cytokine formulation supported the expansion of CD8+ effector
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and effectors/memory phenotypes, regardless of tumor burden of the donors. However,
this formulation provided a different protection for CD4+ T cells such that central
memory phenotypes were the most abundantly expanded cells. Given the expression of
MHC class I but not MHC class II by the tumor cells, CD8+ T cells are expected to play
a more important role against MMC breast tumors than CD4+ T cells. This prediction is
supported by our observation that tumor-specific IFN-γ and perforin productions were
markedly increased in CD8+ rather than in CD4+ T cells upon stimulation with MMC
tumor cells in vitro. In addition, a higher frequency of CD8+ effector T cells with the
sequential gamma chain cytokines compared to those with the alternating gamma chain
cytokines (44-56% vs. 16.8%) was associated with greater tumoricidial activity of T
cells in vitro. Importantly, the number of the CD44 receptors per CD8+ T cells was
greater with sequential gamma chain cytokines compared to those with alternating
gamma chain cytokines (MFI: 30.9 vs. 5.6). Expression of CD44 has been shown to be
the most potent stimulator of Fas ligand expression on human T cells (52) which in turn
may induce apoptosis in Fas positive target cells. We have already shown the
expression of Fas in MMC tumor cells (65). These data suggest that CD8+ effector T
cells may work better against the tumor cells compared to CD8+ central memory T
cells. In fact in vivo tumor challenge studies further confirmed higher efficiency of
CD8+ effector T cells in tumor rejection. While AIT by means of T cells expanded with
the alternating gamma chain cytokines provided no protection against tumor challenge,
those expanded with the sequential common gamma chain cytokines provided complete
protection against tumor challenge even without depletion of MDSCs in vivo. These
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differences in the efficiency of T cells were related to different gamma chain cytokine
formulation rather than the status of tumor burden in the donors, because in both cases
T cells were derived from animals bearing large tumors. Importantly, T cells grown
with the sequential common gamma chain cytokines generated long-term memory
responses not only against MMC tumor cells but also to some extent against challenge
with
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cyclophosphamide treatment because of the reconstitution of tumor-reactive T cells
following AIT. Such T cell reconstitution was confirmed by phenotype analysis of T
cells derived from the recipient animals after the rejection of recall tumor challenge. All
the animals showed high levels of CD8+ effector T cells (26.3%) compared to those
derived from the donors prior to the expansion ex vivo (6-7%). These T cells also
showed anti-tumor efficacy against MMC and ANV in vitro without further expansion
ex vivo. These findings are consistent with previous reports showing that loss of
expression of the lymphoid homing molecules and acquisition of CD44 expression can
be associated with increased anti-tumor effects of adoptively transferred T cells (45).
Status of tumor burden in FVBN202 donors was found to have significant impact on the
efficacy of tumor-specific T cells in vitro. Compared to CD8+ T cells derived from
animals with small tumor burden, those derived from animals with large tumor burden
and expanded with the sequential gamma chain cytokines showed higher levels of
tumor-induced IFN-γ (30% vs. 6.5%) and perforin (84% vs. 6.15%) production as well
as a higher proportion of CD44+ effector phenotypes (56% vs. 44%). Higher efficacy of
these T cells was also confirmed by showing that T cells derived from donors with large
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tumor burden and expanded with the sequential gamma chain cytokines protected
animals against primary and recall tumor challenge whereas those derived from donors
with small tumor burden and expanded with the same sequential gamma chain cytokine
protocol protected animals against primary tumor challenge but whether or not they
may protect animals against recall tumor challenge remains to be determined.
Higher anti-tumor efficacy of T cells expanded with the sequential gamma chain
cytokines compared to alternating gamma chain cytokines was observed despite the
higher levels of apoptotic cells and lower proportion of CD8+ T cells over CD4+ T
cells. This may be related to the fact that continuous presence of IL-7 during the
expansion (with the alternating gamma chain cytokine regimen) could protect T cells
from apoptosis and as a result increase the frequency of T cells that are at late stage of
differentiation and may not last long in vivo after AIT. Higher frequency of central
memory T cells also supports this possibility. On the other hand, continuation of culture
with IL-2 (with the sequential common gamma chain cytokines) results in apoptosis of
T cells that are at late stages of differentiation and rescues those at early stages of
differentiation that could undergo further differentiation in vivo after AIT. Higher
frequency of apoptotic T cells as well as lower proportion of CD8+ central memory T
cells supports this possibility. However this was only the case for CD8+ T cells and
could not explain high proportion of CD4+ central memory T cells. Therefore, a key
element would be whether T cells grown with the sequential gamma chain cytokines
may acquire resistance to inhibitory function of MDSCs, as suggested by in vivo
efficacy of AIT by means of these T cells in the absence of MDSC depletion.
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Sequential common gamma chain cytokine protocol facilitates differentiation and
expansion of tumor-reactive T cells that are refractory to the inhibitory effects of
MDSCs
MDSCs are known to be a major contributor in tumor-induced immune suppression.
Gabrilovich et al. have shown antigen specific contact-dependency of these cells.
MDSCs did exert a detrimental effect on the number of IFN-γ producing CD8+ T cells
in response to specific peptides presented by MHC class I (35). Other reports reveal that
MDSCs may work through downregulation of TCR zeta chain and can cause
dysfunction of T cells described in cancer, infectious diseases and autoimmune
disorders. Alternatively, their suppressive function may be dependent on their
derivation from a chronically inflamed environment (36). Our previous work in
FVBN202 transgeic mouse model of breast carcinoma showed that MDSCs inhibit T
cell activation in a contact-dependent fashion (37).
In vitro co-culture assays showed that T cells expanded with the sequential gamma
chain cytokines were refractory to MDSCs, as evidenced by unaltered production of the
tumor induced IFN-γ, perforin, granzyme B, or expression of the early activation
marker CD69. Importantly, the presence of MDSCs did not inhibit the tumor killing
function of T cells in vitro. Given that the T cell inhibitory function of MDSCs have
been reported by using CD3 activation or tumor-induced activation in vitro, it is likely
that MDSCs could inhibit activation rather than effector function of T cells. Therefore,
they would be expected to inhibit naïve and central memory T cells rather than already
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activated effector T cells. A higher proportion of CD8+ effector T cells with the
sequential gamma chain cytokines compared to those with the alternating gamma chain
cytokines support this possibility. In order to test this possibility we should sort effector
and central memory T cells and perform in vitro suppression assays in the presence or
absence of MDSCs. These experiments will determine whether only CD44+ effector T
cells are refractory to MDSCs and higher proportion of these phenotypes within the
expanded T cells cause them to be refractory to MDSCs. In line with our observation,
other groups reported that MDSC-mediated down regulation of L-selectin to be the
major cause of T cell suppression as T cells must have L-selectin (high) phenotype to
home to lymph nodes and sites of inflammation where they encounter antigen and are
activated. This down regulation perturbs T cell trafficking patterns, thereby inhibiting T
cell activation (41). Again, this report supports the hypothesis that CD62L+ memory T
cells are more sensitive to MDSCs than CD62L- effector T cells.
Recently, there have been several reports on strategies to overcome MDSCs. A previous
pre- clinical report suggests the in vivo administration of all-trans-retinoic acid can
eliminate MDSCs (73). All-trans-retinoic acid is a naturally occurring isomer of retinoic
acid capable of causing differentiation of a human leukemia cell line and acute
promyelopoetic leukemia cells. In vitro experiments with all-trans-retinoic acid show
marked success in removing MDSCs in humans and mice. Combined application of this
compound and cancer vaccines showed reduced immune suppression and better efficacy
of the vaccines (73). Anti-inflammatory triterpenoids such as the synthetic C-28 methyl
ester of 2-cyano-3, 12-dioxooleana-1,9,-dien-28-oic acid (CDDO-Me) have been
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proven to abrogate the immune suppressive functions of MDSCs (74). Other therapeutic
strategies involve application of cytokines, drugs and antibodies for elimination of
MDSCs. Nowak et al. showed that anti- mitotic Gemcitabine can maintain tumor
specific CD8+ and CD4+ T cells, preferentially reducing the B cells (75). Based on
Nowak’s observation, Suzuki et al. tested the application of Gemcitabine, a common
chemotherapeutic

agent,

along

with

immunotherapy

for

neutralizing

the

immunosuppressive effects of MDSCs. Gemcitabine HCL (GEM 2’-deoxy-2’,2’difluorocytidine monohydrochloride) is a base analogue of cytidine that can block DNA
synthesis in the S-Phase thereby stopping cell cycle progression (76). Though all these
strategies achieved partial success, none of them could observe complete reduction of
MDSCs. The novel cytokine regimen that we have established can successfully make T
cells refractory to the inhibitory effects of MDSCs. The ex vivo expanded T cells can
exhibit marked anti-tumor efficacy in vitro as well as in vivo even in presence of
MDSCs. They can even show memory responses without elimination of endogenous
MDSCs. The exact mechanism by which the T cells can overcome the effects of
MDSCs is not known, but one report suggests that Ox-40 ligation can break T cell
anergy and can restore the proliferative capacity of tumor reactive T cells (77).
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CONCLUSIONS
1) T cell expansion with the sequential common gamma chain cytokines results in
comparable expansion, enhanced in vitro cytotoxicity, a lower ratio of CD8+ over
CD4+ T cells, lower levels of tumor-induced IFN-γ production and poorer viability
of the expanded T cells in comparison to the T cells expanded by alternating gamma
chain cytokines.
2) The alternating common gamma chain cytokine formulation supports preferential
differentiation of central/memory phenotypes and effector phenotype of T cells but
the sequential gamma chain cytokine regimen supports differentiation of effector and
effector/memory phenotypes of CD8+ T cells as well as effector and central/memory
phenotype of CD4+T cells. The latter increases the number of CD44 receptors on
CD8+ and CD4+ T cells.
3) T cells expanded with the sequential common gamma chain cytokines can protect
animals from primary neu positive tumor challenge and can exhibit strong memory
responses against neu positive and neu negative tumor challenge.
4) The anti-tumor efficacy of the isolated T cells after the expansion depends on the
status of tumor burden of the donors in addition to the cytokine regimen. T cells
harvested from donors bearing larger tumor burden show greater anti-tumor efficacy
in terms of increased production of IFN-γ and perforin and exhibiting a higher
percentage of CD44+ effector T cell phenotypes.
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5) T cells expanded with the sequential common gamma chain cytokines are refractory
to MDSCs whereas those expanded with the alternating gamma chain cytokines are
susceptible to MDSCs.

The major observations of this study are reproducible and have been repeated 3-4
times. The underlying mechanisms of some of our observations need further
investigation. Thus the future directions of this investigation include:
1) To determine which phenotype of the ex vivo expanded T cell is most effective
in overcoming tumor escape and is refractory to MDSCs.
2) To determine whether T cells harvested from donors with low tumor burden can
exhibit memory responses after the expansion with sequential gamma chain
cytokines.
3) To examine the cytokine-induced expression of receptors (Ox-40/Ox-40L) on T
cells that may render them refractory to MDSCs.
4) To determine the therapeutic efficacy of sequential common gamma chain
cytokines-expanded T cells against spontaneous and transplanted mammary
tumors.
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